

CERTIFICATE OF EXPRESS MAIL (37 CFR 1.10)

Label No. EH386303945US

I hereby certify that the attached papers and/or fee are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service on the date shown below in an envelope addressed to Box PCT, Assistant Commissioner for Patents, Washington D.C. 20231.

Feb. 15, 2001
Date

Mary Rutkowski
Printed Name

Mary Rutkowski
Signature

FORM PTO-1390 (REV 12/29/99)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

PPD 50355/UST

TRANSMITTAL LETTER TO THE UNITED STATES

DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

U. S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/763019

INTERNATIONAL APPLICATION NO.:
PCT/GB99/02720

INTERNATIONAL FILING DATE:
August 17, 1999

PRIORITY DATE CLAIMED:
August 18, 1998

TITLE OF INVENTION:

Polynucleotide Sequences

EXPRESS MAIL NO.:

EH386303945US

APPLICANT(S) FOR DO/EO/US:


Ian EVANS and John RAY

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND or SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1)).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371 (c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
- ☒ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: Information Disclosure Statement, Form PTO-1449, Copies of 4 refs. cited on PTO-1449, Paper Copy of Sequence Listing, Computer Disk Containing Sequence Listing, Statement to Support Filing and Submission under 37 CFR 1.821-1.825

U.S. APPLICATION NO (if known, see 37 CFR 1.5) 09/763019		INTERNATIONAL APPLICATION NO		ATTORNEY'S DOCKET NUMBER PPD 50355/UST	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$ 1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$ 860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO... \$ 710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$ 690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4). \$ 100.00 ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 860.00				CALCULATIONS PTO USE ONLY	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	76-20 =	56	x \$18.00	\$1,008.00	
Independent claims	8 - 3 =	5	x \$80.00	\$ 400.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$ 270.00	
TOTAL OF ABOVE CALCULATIONS =				\$2,538.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$2,538.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				+	
TOTAL NATIONAL FEE =				\$2,538.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	
TOTAL FEES ENCLOSED =				\$2,538.00	
				Amount to be refunded:	\$
				Charged	\$
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 09-0013 in the amount of \$ 2,538.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 09-0013 . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Syngenta Crop Protection, Inc. Intellectual Property Section 2 Righter Parkway P.O. Box 15458 Wilmington, DE 19850-5458			 23698 PATENT TRADEMARK OFFICE		
			SIGNATURE <u>Liza D. Hohenschutz</u> <u>Feb 15, 2001</u> NAME 33,712 REGISTRATION NUMBER (302)476-2088 TELEPHONE NUMBER		

09/763019

JC03 Rec'd PCT/PTO 15 FEB 2001

CERTIFICATE OF EXPRESS MAIL (37 CFR 1.10) Label No. EH386303945US

I hereby certify that the attached papers and/or fee are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service on the date shown below in an envelope addressed to: Assistant Commissioner for Patents, Washington DC 20231.

Feb. 15, 2001
(Date)

Mary Rutkowski
(Printed Name)

Mary Rutkowski
(Signature)

Docket No. PPD 50355/UST

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF.: Ian EVANS et al.

SERIAL NUMBER: Not Assigned

GROUP ART UNIT: Not Assigned

FILED:

EXAMINER: Not Assigned

FOR: Polynucleotide Sequences

Assistant Commissioner for Patents
Washington, DC 20231

Sir:


**STATEMENT TO SUPPORT FILING AND SUBMISSION
IN ACCORDANCE WITH 37 CFR §§1.821 THROUGH 1.825**

- ☒ I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the information recorded in computer readable form is identical to the written Sequence Listing.
- ☒ I hereby state that the submission filed in accordance with 37 C.F.R. 1.821(g) does not include new matter.
- ☐ I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- ☒ I hereby state that the amendments, made in accordance with 37 C.F.R. §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages 1-23 of the Sequence Listing. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- ☒ I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(b), is the same as the amended Sequence Listing.

T06T20"ST06E9Z60

☐ I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.85(d), contains identical data to that originally filed.

Respectfully submitted,
Syngenta Crop Protection, Inc.


Liza B. Hohenschutz

Attorney for Applicant(s)

Reg. No. 33,712

Telephone: 302/476-2088

Dated: February 15, 2001

g:\intelprop\ppd files\ppd50364ust\011801 - state to sup filing.doc

09/763019 071901
FEB 20 6 40 PM '01

CERTIFICATE OF EXPRESS MAIL (37 CFR 1.10) Label No. EH386303945US

I hereby certify that the attached papers and/or fee are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service on the date shown below in an envelope addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington DC 20231.

Feb. 15, 2001
(Date)

Mary Rutkowski
(Printed Name)

Mary Rutkowski
(Signature)

PATENT APPLICATION
PPD 50355/UST

IN THE UNITED STATES ELECTED OFFICE

INTERNATIONAL APPLICATION NO.: PCT/GB99/02720

INTERNATIONAL FILING DATE: August 17, 1999

PRIORITY DATE CLAIMED: August 18, 1998

APPLICANTS: Ian EVANS *et al.*

TITLE: POLYNUCLEOTIDE SEQUENCES

PRELIMINARY AMENDMENT

Box PCT
Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Prior to assigning a serial number and calculating the filing fee, please amend the above-identified application as follows:

IN THE CLAIMS

Claim 8, line 1, delete "preceding claim" and substitute therefor --one of claims 1 to 6--.

Claim 9, line 1, delete "preceding claim" and substitute therefor --one of claims 1 to 6--.

Claim 10, line 2, delete "of the preceding claims" and substitute therefor --any one of claims 1 to 6--.

Claim 11, lines 1 and 2, delete "claims 1 to 9 or the vector of claim 10" and substitute therefor --claims 1 to 6--.

Claim 12, lines 1 and 2, delete "the preceding claim" and substitute therefor --claim 11--.

09763019-01901

13. (amended) The progeny of the plants of claim 12 [the preceding claim, which progeny comprises the polynucleotide of any one of claims 1 to 9 stably incorporated into its genome and heritable in a mendelian manner], the seeds of such plants and such progeny.

Claim 14, line 4, delete "9 or the vector of claim 10" and substitute therefore
--6--.

Claim 15, line 1, delete "9, or the vector of claim 10" and substitute therefor
--6--.

Claim 18, line 2, delete "either of claims 12 or 13" and substitute therefor
--claim 12.


Claim 19, line 1, delete "9, or the vector of claim 10" and substitute therefore --6--.

REMARKS

The claims have been amended to remove improper multiple dependencies and place them in a better form for examination.

An early and favorable Office Action is requested.

Respectfully submitted,
Syngenta Crop Protection, Inc.


Liza D. Hohenschutz
Reg. No. 33,712
Attorney for Applicants

Dated: February 15, 2001
2 Righter Parkway
P.O. Box 15458
Wilmington, DE 19850-5458
Telephone: (302) 476-2088

g:\intelprop\ppd files\ppd50355ust\011801 - preliminary amendment.doc

09/763019
JC03 Rec'd PCT/PTO 15 FEB 2001

CERTIFICATE OF EXPRESS MAIL (37 CFR 1.10) Label No. EH386303945US

I hereby certify that the attached papers and/or fee are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service on the date shown below in an envelope addressed to: Box PCT, Assistant Commissioner for Patents, Washington DC 20231.

Feb. 15, 2001
(Date)

Mary Rutkowski
(Printed Name)

Mary Rutkowski
(Signature)

PATENT APPLICATION
PPD 50355/UST

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF.: Ian Evans et al.

SERIAL NUMBER: Not Assigned

GROUP ART UNIT: Not Assigned

FILED:

EXAMINER: Not Assigned

FOR: Polynucleotide Sequences

SECOND PRELIMINARY AMENDMENT

Box PCT
Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Prior to a first Official Action, please amend the above-identified patent application as follows:

IN THE SEQUENCE LISTING:

Delete the Sequence Listing (pages 1-23) and insert the Sequence Listing submitted herewith.


REMARKS

Applicants submit a paper copy of the Sequence Listing in compliance with 37 CFR 1.821-1.825, a computer disk containing the Sequence Listing in computer readable form and a Statement to Support Filing and Submission in Accordance with 37 CFR 1.821-1.825.

09/763019-071901

An early and favorable Office Action is requested.

Respectfully submitted,
Syngenta Crop Protection, Inc.



Liza D. Hohenschutz
Reg. No. 33,712
Attorney for Applicants

Dated: February 15, 2001
2 Righter Parkway
P.O. Box 15458
Wilmington, DE 19850-5458
Telephone: (302) 476-2088

g:\intelprop\ppd files\ppd50355ust\011801 - 2nd prel amend.doc

09763049-074001
T06170"5T0E9Z69

POLYNUCLEOTIDE SEQUENCES

The present invention relates to recombinant DNA technology, and in particular to nucleotide sequences (and expression products thereof) which are used in the production of transgenic plants.

5 The present invention provides, inter alia, nucleotide sequences useful in the production of plants which show improved resistance to infection by microorganisms such as bacteria and fungi.

According to the present invention there is provided a polynucleotide comprising a sequence selected from those depicted in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ
10 ID No. 4 and SEQ ID No. 5.

Also included within the invention is the translation product of the said polynucleotide sequences depicted in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4 and SEQ ID No. 5.

The invention further provides a polynucleotide sequence comprising a sequence
15 selected from the group consisting of nucleotides 53 to 385 in SEQ ID No. 1, nucleotides 11 to 334 in SEQ ID No. 2, nucleotides 24 to 317 in SEQ ID No. 3, nucleotides 20 to 343 in SEQ ID No. 4 or nucleotides 1 to 446 in SEQ ID No. 5. Also included within the invention is the translation product of the region comprised by nucleotides 53 to 385 in SEQ ID No. 1, by nucleotides 11 to 334 in SEQ ID No. 2, by nucleotides 24 to 317 in SEQ ID No. 3 or by
20 nucleotides 20 to 343 in SEQ ID No. 4 or nucleotides 1 to 446 in SEQ ID No. 5 and protein having an amino acid sequence which is at least 85% similar to said product. The said translation product is a preproprotein comprising a signal sequence, protein encoding sequence and C-terminal propeptide which is naturally processed to yield mature biologically active protein.

25 The invention further provides a polynucleotide sequence comprising a sequence selected from the group consisting of nucleotides 137 to 286 in SEQ ID No. 1, nucleotides 95 to 244 in SEQ ID No. 2, nucleotides 108 to 257 in SEQ ID No. 3, nucleotides 104 to 253 in SEQ ID No. 4 or nucleotides 177 to 326 in SEQ ID No. 5. These polynucleotide sequences are especially preferred. Also included within the invention and especially
30 preferred is the translation product of the region comprised by nucleotides 137 to 286 in SEQ ID No. 1, by nucleotides 95 to 244 in SEQ ID No. 2, by nucleotides 108 to 257 in SEQ ID

09/763019

No. 3 or by nucleotides 104 to 253 in SEQ ID No. 4 and protein having an amino acid sequence which is at least 95% similar to said product. The translation product is an antimicrobial protein. The related antimicrobial proteins DmAMP1 and Dm-AMP2 have been described in Published International Patent Application No. WO 93/05153 and in
5 Osborn et al (1995) FEBS Lett. 368 257-262.

The invention further provides a polynucleotide sequence comprising a sequence selected from the group consisting of nucleotides 287 to 385 in SEQ ID NO. 1, nucleotides 245 to 334 in SEQ ID No. 2, nucleotides 258 to 317 in SEQ ID No. 3, nucleotides 254 to 343 in SEQ ID No. 4 or nucleotides 327 to 446 in SEQ ID No.5. These nucleotides are
10 particularly preferred according to the invention and encode protein sequences which may be used as cleavable linkers in the co-expression of multiple proteins as is described further herein. The invention further extends to the translation product of nucleotides 287 to 385 in SEQ ID NO. 1, nucleotides 245 to 334 in SEQ ID No. 2, nucleotides 258 to 317 in SEQ ID No. 3, nucleotides 254 to 343 in SEQ ID No. 4 or nucleotides 327 to 446 in SEQ ID No.5
15 and protein having an amino acid sequence which is at least 85% similar to said product.

The invention further provides a polynucleotide sequence comprising a sequence selected from the group consisting of nucleotides 53 to 136 in SEQ ID No. 1, nucleotides 11 to 94 in SEQ ID No.2, nucleotides 24 to 107 in SEQ ID No. 3, nucleotides 20 to 103 in SEQ ID No. 4 or nucleotides 1 to 176 in SEQ ID No. 5 excluding the sequence encoding the
20 intron marked at positions 65 to 156. These nucleotide sequences are signal sequences which may be linked to homologous and heterologous protein encoding regions to transport proteins extracellularly. The invention further extends to the use of said sequences as signal sequences. The invention further extends to the translation product of nucleotides 53 to 136 in SEQ ID No. 1, nucleotides 11 to 94 in SEQ ID No.2, nucleotides 24 to 107 in SEQ ID No. 3, nucleotides 20 to 103 in SEQ ID No. 4 or nucleotides 1 to 176 in SEQ ID No. 5 and
25 protein having an amino acid sequence which is at least 85% similar to said product.

It is preferred that the degree of similarity is at least 90%, more preferred that the degree of similarity is at least 95% and still more preferred that the degree of similarity is at least 97%.

30 In the context of the present invention, two amino acid sequences with at least 85% similarity to each other have at least 85% similar (identical or conservatively replaced)

amino acid residues in a like position when aligned optimally allowing for up to 3 gaps, with the proviso that in respect of the gaps a total of not more than 15 amino acid residues is affected. Likewise, two amino acid sequences with at least 90% similarity to each other have at least 90% identical or conservatively replaced amino acid residues in a like position when aligned optimally allowing for up to 3 gaps with the proviso that in respect of the gaps a total of not more than 15 amino acid residues is affected.

For the purpose of the present invention, a conservative amino acid is defined as one which does not alter the activity/function of the protein when compared with the unmodified protein. In particular, conservative replacements may be made between amino acids within the following groups:

- (i) Alanine, Serine, Glycine and Threonine
- (ii) Glutamic acid and Aspartic acid
- (iii) Arginine and Lysine
- (iv) Isoleucine, Leucine, Valine and Methionine
- (v) Phenylalanine, Tyrosine and Tryptophan

Sequence alignments to measure sequence similarity may be produced using the Lasergene program MegAlign (supplied by DNASTAR Inc. 1228 S. Park St. Madison WI 53715, USA). The Clustal Method and the PAM250 residue weight table with the following parameters may be used:

Multiple Alignment Parameters

gap penalty 10

gap length penalty 10

Pairwise alignment parameters

Ktuple 1

gap penalty 3

window 5

Diagonals saved 5

The invention also includes a polynucleotide encoding a protein having a substantially similar activity to any one of the group selected from those encoded by SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4 or SEQ ID No. 5, which polynucleotide is complementary to one which when incubated at a temperature of between 55 and 65°C in a

solution containing 5 X SSC (saline sodium citrate buffer) containing 0.1% SDS and 0.25% powdered skimmed milk followed by washing at the same temperature with 0.1, 0.5 or 2x SSC containing 0.1% SDS still hybridises with a sequence depicted in SEQ ID No 1, SEQ ID No 2, SEQ ID No3, SEQ ID No.4 or SEQ ID No.5 with the proviso that the sequence is not that described in SEQ ID No.6 or 7.

The polynucleotide sequence provided in SEQ ID Nos 6 and 7 is the predicted DNA sequence for Dm-AMP1 and Dm-AMP2 as described in Figure 31A of Published International Patent Application No. WO 93/05153.

The invention still further includes a polynucleotide encoding a protein having a substantially similar activity to any one of the group selected from that encoded by nucleotides 53 to 385 in SEQ ID No. 1, by nucleotides 11 to 334 in SEQ ID No. 2, by nucleotides 24 to 317 in SEQ ID No. 3, by nucleotides 20 to 343 in SEQ ID No. 4 or by nucleotides 1 to 446 in SEQ ID No.5 which polynucleotide is complementary to one which when incubated at a temperature of between 55 and 65°C in a solution containing 5 X SSC (saline sodium citrate buffer) containing 0.1% SDS and 0.25% powdered skimmed milk followed by washing at the same temperature with 0.1, 0.5 or 2x SSC containing 0.1% SDS still hybridises with a sequence depicted by nucleotides 53to 385 in SEQ ID No. 1, by nucleotides 11 to 334 in SEQ ID No. 2, by nucleotides 24 to 317 in SEQ ID No. 3, by nucleotides 20 to 343 in SEQ ID No. 4 or by nucleotides 1 to 446 in SEQ ID No.5. with the proviso that said sequence is not that described in SEQ ID No. 6 or SEQ ID No. 7.

The invention still further includes a polynucleotide encoding a protein having a substantially similar activity to any one of the group selected from that encoded by nucleotides 137 to 286 in SEQ ID No. 1, by nucleotides 95 to 244 in SEQ ID No. 2, by nucleotides 108 to 257 in SEQ ID No. 3, by nucleotides 104 to 253 in SEQ ID No. 4 or by nucleotides 177 to 326 in SEQ ID No.5 which polynucleotide is complementary to one which when incubated at a temperature of between 55 and 65°C in a solution containing 5 X SSC (saline sodium citrate buffer) containing 0.1% SDS and 0.25% powdered skimmed milk followed by washing at the same temperature with 0.1, 0.5 or 2x SSC containing 0.1% SDS still hybridises with a sequence depicted by nucleotides 137 to 286 in SEQ ID No. 1, by nucleotides 95 to 244 in SEQ ID No. 2, by nucleotides 108 to 257 in SEQ ID No. 3, by

nucleotides 104 to 253 in SEQ ID No. 4 or by nucleotides 177 to 326 in SEQ ID No.5. with the proviso that said sequence is not that described in SEQ ID No. 6 or SEQ ID No. 7.

The invention still further includes a polynucleotide encoding a protein having a substantially similar activity to any one of the group selected from that encoded by
5 nucleotides 287 to 385 in SEQ ID NO. 1, nucleotides 245 to 334 in SEQ ID No. 2, nucleotides 258 to 317 in SEQ ID No. 3, nucleotides 254 to 343 in SEQ ID No. 4 or nucleotides 327 to 446 in SEQ ID No.5. which polynucleotide is complementary to one which when incubated at a temperature of between 55 and 65°C in a solution containing 5 X SSC (saline sodium citrate buffer) containing 0.1% SDS and 0.25% powdered skimmed milk
10 followed by washing at the same temperature with 0.1, 0.5 or 2x SSC containing 0.1% SDS still hybridises with a sequence depicted by nucleotides 287 to 385 in SEQ ID NO. 1, nucleotides 245 to 334 in SEQ ID No. 2, nucleotides 258 to 317 in SEQ ID No. 3, nucleotides 254 to 343 in SEQ ID No. 4 or nucleotides 327 to 446 in SEQ ID No.5. with the proviso that said sequence is not that described in SEQ ID No. 6 or SEQ ID No. 7.

15 It may be desired to target the translation products of the polynucleotide to specific sub-cellular compartments within the plant cell, in which case the polynucleotide comprises sequences encoding chloroplast transit peptides, cell wall targeting sequences etc. immediately 5' of the regions encoding the said translation products.

Translational expression of the protein encoding sequences contained within the
20 polynucleotide may be relatively enhanced by including known non translatable translational enhancing sequences 5' of the said protein encoding sequences. The skilled man is very familiar with such enhancing sequences, which include the TMV-derived sequences known as omega, and omega prime, as well as other sequences derivable, inter alia, from the regions 5' of other viral coat protein encoding sequences.

25 In a particularly preferred embodiment of the invention, the polynucleotide is modified in that mRNA instability motifs and/or fortuitous splice regions are removed, or plant preferred codons are used so that expression of the thus modified polynucleotide in a plant yields substantially similar protein having a substantially similar activity/function to that obtained by expression of the unmodified polynucleotide in the organism in which the
30 protein encoding regions of the unmodified polynucleotide are endogenous, with the proviso that if the thus modified polynucleotide comprises plant preferred codons, the degree of

identity between the modified polynucleotide and a polynucleotide endogenously contained within the said plant and encoding substantially the same protein is less than about 60%.

The invention also includes a plant transformation vector comprising a plant operable promoter, a polynucleotide sequence comprising all or part of the sequence selected from those depicted in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4 and SEQ ID No.5 under the transcriptional control thereof and encoding an antimicrobial protein, and a plant operable transcription terminator. The promoter may be constitutive or inducible. In particular, the promoter may be such that it induces transcription in response to application to the plant material containing it of a chemical.

The invention further provides a plant transformation vector comprising a polynucleotide sequence selected from the group consisting of nucleotides 137 to 286 in SEQ ID No. 1, nucleotides 95 to 244 in SEQ ID No. 2, nucleotides 108 to 257 in SEQ ID No. 3, nucleotides 104 to 253 in SEQ ID No. 4 or nucleotides 177 to 326 in SEQ ID No.5 under the transcriptional control of a plant operable promoter, and a plant operable transcriptional terminator.

The polynucleotide sequences provided in SEQ ID No 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4 and SEQ ID No.5 are related sequences with the translated products thereof showing a high degree of sequence similarity and it is believed that they may belong to a multi gene family.

The invention still further includes plant tissue transformed with the said polynucleotide or vector, and material derived from the said transformed plant tissue, as well as morphologically normal fertile whole plants comprising the tissue or material. Such transformed plants include but are not limited to, field crops, fruits and vegetables such as canola, sunflower, tobacco, sugar beet, cotton, maize, wheat, barley, rice, sorghum, tomato, mango, peach, apple, pear, strawberry, banana, melon, potato, carrot, lettuce, cabbage, onion, etc. Particularly preferred genetically modified plants are bananas.

The invention still further includes the progeny of the plants of the preceding paragraph, which progeny comprises a polynucleotide of the invention stably incorporated into its genome and heritable in a mendelian manner and the seeds of such plants and such progeny.

The invention also provides a method of producing plants which are substantially tolerant or substantially resistant to antimicrobial infection, comprising the steps of:

- (i) transforming plant material with a polynucleotide or vector of the invention;
- (ii) selecting the thus transformed material; and
- 5 (iii) regenerating the thus selected material into morphologically normal fertile whole plants.

Plant transformation, selection and regeneration techniques, which may require routine modification in respect of a particular plant species, are well known to the skilled man.

10 The invention also provides the use of a polynucleotide as described herein or a vector described herein in the production of plant tissues and/or morphologically normal fertile whole plants which are substantially tolerant or substantially resistant to microbial infection.

In a further aspect the invention provides a method of selectively controlling
15 microorganisms at a locus comprising the plants, progeny and/or seeds described herein comprising applying to the locus a microorganism controlling amount of the translation product of the region comprised by nucleotides 137 to 286 in SEQ ID No. 1.; nucleotides 95 to 244 in SEQ ID No.2, nucleotides 108 to 257 in SEQ ID No. 3, or nucleotides 104 to 253 in SEQ ID No. 4.

20 In a still further aspect the invention provides the use of a polynucleotide according to the invention described herein , or a vector as described herein in the production of an antimicrobial protein.

The invention will be further apparent from the following description taken in conjunction with the associated figures and sequence listings in which :

25 Figure 1 shows the polynucleotide and corresponding amino acid sequences for A) Dm1 (SEQ ID No5) and B) Dm2.18 (SEQ ID No1),
Figure 2 shows the polynucleotide and corresponding amino acid sequences for A) Dm2.1 (SEQ ID No2) and B) Dm2.3 (SEQ ID No3),

Figure 3 shows the polynucleotide and corresponding amino acid sequence for Dm2.5 (SEQ ID No. 4),

Figure 4 shows a diagrammatic map of plasmids pMJB1, pDmAMPD and pDmAMPE;

Figure 5 shows a diagrammatic map of plasmid pFAJ3106;

5 Figure 6 shows a diagrammatic map of plasmid pFAJ3109

Figure 7 shows the nucleotide sequence between the XhoI and SacI sites of pFAJ3106;

Figure 8 shows the nucleotide sequence between the XhoI and SacI sites of pFAJ3109;

Figure 9 shows a diagrammatic map of plasmid pZPS38;

Figure 10 shows a diagrammatic map of plasmid pZPS34;

10 Figure 11 shows a diagrammatic map of plasmid pZPS35;

Figure 12 shows a diagrammatic map of plasmid pZPS37.

Figure 13 shows a plan of the construction of the Dm-AMP gene

Figure 14 shows one predicted polynucleotide sequence for DmAMP1 (SEQ ID No. 6) and Dm-AMP2 (SEQ ID No. 7).

15 Figure 15 shows a diagrammatic map of plasmid pAID-MR7

EXAMPLE 1

Dm Gene Isolation and Vector Construction

20 Dahlia cDNA library construction

Near-dry seeds were collected from flowers of *Dahlia merkii*.

Total RNA was purified from the seeds using the method of Jepson et al. (Plant Molecular Biology Reporter 9 131-138 (1991)).

Seeds were frozen in liquid nitrogen and ground to a fine powder using a mortar and pestle.

25 Phenol/m-cresol (9:1) was added followed by RNA homogenisation buffer and the mixture ground until a fine paste was obtained. The mixture was spun, the aqueous phase collected and extracted twice with phenol/chloroform (1:1). Lithium chloride (12 M) was added to the resulting aqueous layer to a final concentration of 2 M and incubated overnight at 4°C.

Precipitated RNA was collected by spinning at 13,000 rpm in an Eppendorf centrifuge and
30 the RNA pellet re-suspended in 5 mM Tris-HCl, pH 7.5. A second overnight lithium chloride

precipitation was carried out and the RNA collected and re-suspended in 5 mM Tris-HCl, pH 7.5.

0.6 mg of total RNA was obtained from 2 g of *D. merkii* seed.

PolyAtract magnetic beads (Promega) were used to isolate approximately 2 µg poly-A⁺

RNA from 0.2 mg of total RNA.

The poly-A⁺ RNA was used to construct a cDNA library using a ZAP-cDNA synthesis kit (Stratagene). Following first and second strand synthesis double stranded cDNA was size fractionated on a Sephacryl S-400 column. The three largest cDNA size fractions were pooled and ligated with vector DNA. After phage assembly using Gigapack Gold

(Stratagene) packaging extracts, approximately 1×10^5 pfu were obtained.

Probing

Dahlia genomic DNA was prepared from 100 mg of developing Dahlia seeds and flower tissue. Tissue was homogenised in a 1.5 ml Eppendorf tube with a conical plastic pestle. 400 µl of a solution containing 0.2M Tris-HCl pH 8.5, 0.25M NaCl, 0.025 M EDTA and 0.5% SDS was added and the tube vortexed for 5 seconds. Cell debris was pelleted by spinning at 13,000 rpm for 1 minute in a MSE bench top micro centrifuge. 300 µl of aqueous extract was transferred to a fresh Eppendorf tube. Genomic DNA was precipitated by the addition of 300 µl isopropyl alcohol and incubation at room temperature for 2 minutes. Genomic DNA was pelleted by spinning at 13,000 rpm for 5 minutes. The ethanol/aqueous supernatant was removed from the tube by pipette and the genomic DNA pellet allowed to air dry. Genomic DNA was then resuspended in 30 µl H₂O.

To amplify a 144 bp fragment of DNA encoding 48 amino acids of the mature Dm-AMP1 a PCR was carried out with Dahlia genomic DNA and oligonucleotides AFP-5 (based on Dm-AMP1 N-terminal amino acid sequence CEKASKTW) and AFP-3EX (based on Dm-AMP1 C-terminal amino acid sequence MCFCYFNC). Using the following conditions 94°C, 60 seconds, 48°C, 12 seconds and 72°C, 60 seconds for 35 cycles. A PCR product of approximately 150 bp was isolated from a 2% agarose gel by electroelution and ethanol precipitation. The PCR product was cloned into pBluescript by ligating blunt Bluescript vector and gel isolated PCR product together using T4DNA ligase and transforming into competent *E. coli* MC1022 cells. Transformation mixes were plated onto L-agar plates containing 100 µg/ml ampicillin and incubated at 37°C for 16 hours. Colonies were picked

and cells shaken for 16 hours in 3 ml L-broth containing 100 µg/ml ampicillin at 37°C. Plasmid DNA was prepared from colonies using a Promega Wizard mini-prep kit. The inserts of 10 transformants were sequenced using a Sequenase kit (United States Biochemical). The cloned PCR product sequences represented 3 Dm-AMP1 related genes.

5 PCR clone 4 contained the DNA sequence

AAGACGTGGTCGGGAAACTGTGGCAATACGGG

ACATTGTGACAACCAATGTAAATCATGGGAGGGTGCGGCCCATGGAGCGTGTCA
TGTGCGTAATGGGAAACACATGTGTTTCTGCTACTTCAAC, encoding a portion of
the observed mature Dm-AMP1 protein sequence (KTWSGNCGNTGHCD

10 NQCKSWEAAHGACHVRNGKHMCFYFN).

The 144 bp PCR product mixture labelled with α^{32} -P d-CTP was used to probe Hybond N (Amersham) filter lifts made from plates containing a total of 6×10^4 pfu of the cDNA library. The filters were hybridised at 46°C for 18 hrs in 5 x SSC, 0.1% SDS, 0.25% skimmed milk powder. Filters were washed in 2 x SSC, 0.1% SDS at 60°C. Autoradiography
15 was carried out at -70°C with intensifying screens. Thirty potentially positive signals were observed. 22 plaques were picked and taken through two further rounds of screening. After in vivo excision 13 clones were characterised by DNA sequencing.

Four classes of Dm-AMP related peptide were encoded by the 13 cDNA clones and the sequences of these peptides are provided in SEQ ID Nos 1- 4 in the accompanying figures.

20 Three versions of the Dm-AMP core region were represented in the four classes. One of the classes (Dm2.5 type) contained a core region which may correspond to Dm-AMP2.

None of the cDNAs encoded a core region equivalent to the observed mature Dm-AMP1 peptide sequence.

Isolation of a Mature Dm-AMP1 Gene

25 Using the sequence of PCR clone 4 (above) and information from the NH₂ and COOH ends of the peptides described by cDNA sequences two pairs of oligonucleotides were designed for amplification of a gene encoding the observed mature Dm-AMP1.

A PCR was carried out with Dahlia genomic DNA and oligonucleotides MATAFP-5P (based on the codons present in Dm2.1, Dm2.3, Dm2.18 and Dm2.5 encoding the N-terminal amino
30 acid sequence M(AV)(KN)(NR)SVAF) and MATAFP-5 (based on the mature Dm-AMP1 amino acid sequence NGKHMCF) using the following conditions; 94°C, 60 seconds, 53°C,

12 seconds and 72°C, 60 seconds for 40 cycles. A PCR product of approximately 220 bp was isolated from a 2% agarose gel by electroelution and ethanol precipitation. The PCR product was cloned into pBluescript and clones sequenced as described above. A clone containing the 5' half of a Dm-AMP1 gene was identified.

- 5 A PCR was carried out with Dahlia genomic DNA and oligonucleotides MATAFP-3 (based on the mature Dm-AMP1 amino acid sequence GACHVRN) and DM25MAT-3 (based on the last two amino acids and the 3' untranslated region of Dm2.5) using the following conditions; 94°C, 60 seconds, 53°C, 12 seconds and 72°C, 60 seconds for 40 cycles. A PCR product of approximately 170 bp was isolated from a 2% agarose gel by electroelution and ethanol precipitation. The PCR product was cloned into pBluescript and clones were sequenced as described above. A clone containing the 3' half of a Dm-AMP1 gene was identified.

The 5' and 3' sections of the mature gene were combined to assemble the sequence of the mature Dm-AMP1 gene (see Figure 1 SEQ ID No.5) which is comprised of exon 1, 64 bp encoding part of the leader peptide, 92 bp intron and exon 2 encoding the end of the leader sequence, Dm-AMP1 core and C-terminal extension.

Vector Oligonucleotide design

Four oligonucleotides were designed based on the DNA sequence of the mature Dm-AMP1 gene:

- 20 DMVEC-1 top strand priming at the 5' end of the mature DmAMP-1 gene incorporating a Nco I site at the translation start of DmAMP-1 allowing cloning into pMJB1 (see Figure 4).
DMVEC-2 bottom strand priming in the 3' end of the C-terminal extension and a Sac I site for cloning in pMJB1.

- DMVEC-3 top strand priming at the 5' end of the mature DmAMP-1 gene incorporating a Nco I site at the translation start of DmAMP-1 allowing cloning into pMJB1 also encoding complete signal peptide (minus intron).

DMVEC-4 bottom strand priming in the 3' end of the core region and a Sac I site for cloning in pMJB1.

- A PCR was carried out with Dahlia genomic DNA and oligonucleotides DMVEC-1 and
30 DMVEC-2 using the following conditions; 94°C, 60 seconds, 60°C, 12 seconds and 72°C, 60 seconds for 45 cycles. A PCR product of approximately 450 bp spanning the mature Dm-

AMP1 gene was obtained, this PCR product was isolated from an agarose gel and used as a template for PCRs described in vector construction below.

Vector Construction

5 pDmAMPD

A PCR was carried out with the DMVEC-1 and DMVEC-2 450 bp PCR product and oligonucleotides DMVEC-1 and DMVEC-4 using the following conditions, 94°C, 48 seconds, 58°C, 12 seconds and 72°C, 90 seconds for 33 cycles. The PCR product was cut with Nco I and Sac I the 60 bp Nco I/Sac I fragment was isolated and ligated with pMJB1 cut
10 with Nco I and Sac I. The ligation mix was used to transform competent *E. coli* MC1022 cells and plasmid DNA of ampicillin resistant transformants was obtained as described above.

The identity of the fragment in one of the resulting transformants was confirmed by sequencing, the clone was termed pDmAMPA.

15 A PCR was carried out with the DMVEC-1 and DMVEC-2 450 bp PCR product and oligonucleotides DMVEC-3 and DMVEC-4 using the following conditions; 94°C, 48 seconds, 58°C, 12 seconds and 72°C, 90 seconds for 33 cycles. The PCR product was cut with Nco I, the resulting 150 bp Nco I fragment isolated and cloned into pDmAMPA cut with Nco I. DNA sequencing confirmed that one transformant termed pDmAMPD, contained
20 DNA encoding Dm-AMP leader and core region.

pDmAMPE

The PCR product obtained with DMVEC-1 and DMVEC-2 was cut with Nco I and Sac I the 180 bp Nco I/Sac I fragment was isolated and cloned into pMJB1 cut with Nco I and Sac I as described above.

25 The identity of the fragment in one of the resulting transformants was confirmed by sequencing, the clone was termed pDmAMPB.

A PCR was carried out with the DMVEC-1 and DMVEC-2 450 bp PCR product and oligonucleotides DMVEC-3 and DMVEC-4 using the following conditions; 94°C, 48 seconds, 58°C, 12 seconds and 72°C, 90 seconds for 33 cycles. The PCR product was cut
30 with Nco I and the resulting 150 bp Nco I fragment isolated and cloned into pDmAMPB cut

with Nco I. DNA sequencing confirmed that one transformant termed pDmAMPE, contained DNA encoding Dm-AMP leader, core and C-terminal extension.

Both pDmAMPD and pDmAMPE vector sequences contained PCR derived base substitutions with respect to Dm-AMP1 gene DNA sequence however the base changes were silent having no effect on the expected amino acid sequence.

AFP-5 (to CEKASKTW)

TG(T,C)GANAANGCN(A,T)(G,C)NAA(A,G)ACNTGG

AFP-3EX (to MCFCYFNC)

CA(A,G)TT(A,G)AANTANCANAAA(A,G)CACAT

10 MATAFP-5P

ATGGC(C,G)AAN(A,C)(A,G)NTC(A,G)GTTGCNTT

MATAFP-5

AAACACATGTGTTTCCCATT

MATAFP-3

15 AGCGTGTCATGTGCGTAAT

Dm25MAT-3

TAAAGAAACCGACCCTTTCACGG

DMVEC-1

ATCGTAGCCATGGTGAATCGGTCGGTTGCGTTCTCCGCG

20 DMVEC-2

AAACCGACCGAGCTCACGGATGTTCAACGTTTGGAAAC

DMVEC-3

ATGCATCCATGGTGAATCGGTCGGTTGCGTTCTCCGCGTTGTTCTGATCCTTTTC
GTGCTCGCCATCTCAGATATCGCATCCGTTAGTGGAGAACTATGCGAGAAA

25 DMVEC-4

AGCAAGCTTTTCGGGAGCTCAACAATTGAAGTAA

30

EXAMPLE 2

Constructions of plant transformation vectors

Expression cassettes containing a Dm-AMP1 open reading frame functionally linked to an enhanced 35S promoter, a TMV omega translational enhancer and a Nos 3' region are isolated as restriction fragments. pDmAMPD and pDmAMPE are both digested with the restriction endonucleases HindIII and EcoRI and the appropriate restriction fragment isolated and purified. Each fragment is ligated into a binary vector (a pBIN19 derivative named pBin19i) which has also been digested with HindIII and EcoRI. The resulting constructs, named pDmAMPLC and pDmAMPLCC, incorporate the expression cassettes from pDmAMPD and pDmAMPE respectively.

pDmAMPLC and pDmAMPLCC are subsequently introduced into *Agrobacterium tumefaciens* strain LBA4404 and introduced into tobacco and oil seed rape using standard plant transformation methodology.

Plants are regenerated from callus tissue resistant to the selective agent kanamycin and expression of the Dm-AMP1 product is monitored by standard Western blot or ELISA methods using antibody which had been raised against Dm-AMP1 protein. A range of expression levels are detected. The Dm-AMP1 expressed in selected transgenic is further characterised following extraction and partial purification from leaves of such lines. The product is of the predicted mass, as indicated by mass spectrometry. It is also demonstrated to retain biological activity after extraction as demonstrated by retention of antifungal activity in in-vitro (micro-titre plate) assays.

EXAMPLE 3

Constructions of plant transformation vectors for polyprotein expression

Schematic representations of the plant transformation vectors used in this work, pFAJ3106 and pFAJ3109, are shown in figures 5 and 6, respectively. The nucleotide sequences comprised between the XhoI and SacI sites of these plasmids, which encompass the regions encoding antimicrobial proteins, are presented in Figures 7 and 8. The regions comprised between the XhoI and SacI sites of plasmid pFAJ3106 (shown in Figure 7) was constructed following the two-step recombinant PCR protocol of Pont-Kindom G.A.D. (1994, Biotechniques 16, 1010-1011). Primers OWB175 (5'AGGAAGTTCATTTCATTTGG) and OWB279 (5'-GCCTTTGGCACAACCTTCTGCCTCTTCCGATGAGTTGTTTCGGCTTTAAGTTTGTC); were used in a first PCR reaction with plasmid pDMAMPE (see above) as a template. The second PCR reaction was done using as a template plasmid pFRG4 (Terras F.R.G. et al., 1995,

Plant Cell 7, 573-588) and as primers a mixture of the PCR product of the first PCR reaction, primer OWB175 and primer OWB172 (5'TTAGAGCTCCTATTAACAAGGAAAGTAGC, SacI site underlined). The resulting PCR product was digested with XhoI and SacI and cloned into the expression cassette vector pMJB1 (see above). The expression cassette in the
5 resulting plasmid, called pFAJ3099, was digested with HindIII (flanking the 5' end of the CaMV35S promoter) and EcoRI (flanking the 3' end of the nopaline synthase terminator) and cloned in the corresponding sites of the plant transformation vector pGPTVbar (Becker D. et al., 1992, Plant Mol. Biol. 20, 1195-1197) to yield plasmid pFAJ3106.

Plasmid pFAJ3109 was constructed by cloning the HindIII-EcoRI fragment of plasmid
10 pDMAMPD (see above) into the corresponding sites of plant transformation vector pGPTVbar (see above).

Plant transformation

Arabidopsis thaliana ecotype Columbia-O was transformed using recombinant Agrobacterium tumefaciens by the inflorescence infiltration method of Bechtold N. et al. (1993, C.R. Acad.
15 Sci. 316, 1194-1199). Transformants were selected on a sand/perlite mixture subirrigated with water containing the herbicide Basta (Agrevo) at a final concentration of 5 mg/l for the active ingredient phosphinothricin.

Elisa assays and protein assays

Antisera were raised in rabbits injected with either RsAFP2 (purified as described in Terras
20 F.R.G. et al., 1992, J. Biol. Chem. 267, 15301-15309) or DmAMP1 (purified as in Osborn R.W. et al., 1995, FEBS Lett. 368, 257-262). ELISA assays were set up as competitive type assays essentially as described by Penninckx I.A.M.A. et al. (1996, Plant Cell 8, 2309-2323). Coating of the ELISA microtiter plates was done with 50 ng/ml RsAFP2 or DmAMP1 in coating buffer. Primary antisera were used as 1000- and 2000-fold diluted solutions
25 (DmAMP1 and RsAFP2, respectively) in 3 % (w/v) gelatin in PBS containing 0.05 % (v/v) Tween 20.

Total protein content was determined according to Bradford (1976, Anal. Biochem. 72, 248-254) using bovine serum albumin as a standard.

Purification and characterisation of expressed proteins

30 Arabidopsis leaves were homogenized under liquid nitrogen and extracted with a buffer consisting of 10 mM NaH₂PO₄, 15 mM Na₂HPO₄, 100 mM KCl, 1.5 M NaCl. The

homogenate was heated for 10 min at 85°C and cooled down on ice. The heat-treated extract was centrifuged for 15 min at 15 000 x g and was injected on a reserved phase high pressure liquid chromatography column (RP-HPLC) consisting of C8 silica (0,46 cm x 25 cm; Rainin) equilibrated with 0.1 % (v/v) trifluoroacetic acid (TFA). The column was eluted at 1 ml/min in a linear gradient in 35 min. from 15 % to 50 % (v/v) acetonitrile in 0.1 % (v/v) TFA. The eluate was monitored for absorbance at 214 nm, collected as 1 ml fractions, evaporated and finally redissolved in water. The fractions were tested by ELISA assays.

Preparation of extracellular fluid and intracellular extract

Intercellular fluid was collected from Arabidopsis leaves by immersing the leaves in a beaker containing extraction buffer (10 mM NaH₂PO₄, 15 mM Na₂HPO₄, 100 mM KCl, 1.5 M NaCl). The beaker with the leaves was placed in a vacuum chamber and subjected to six consecutive rounds of vacuum for 2 min followed by abrupt release of vacuum. The infiltrated leaves were gently placed in a centrifuge tube on a grid separated from the tube bottom. The intercellular fluid was collected from the bottom after centrifugation of the tubes for 15 min at 1800 x g.

The leaves were resubjected to a second round of vacuum infiltration and centrifugation and the resulting (extracellular) fluid was combined with that obtained after the first vacuum infiltration. After this step the leaves were extracted in a Phastprep (BIO101/Savant) reciprocal shaker and the extract clarified by centrifugation (10 min at 10,000 x g) and the resulting supernatant considered as the intracellular extract.

Characterization of transgenic plants and expression analysis

To explore the possibility of expressing polyprotein precursor genes in plants, three different plant transformation vectors were made with the aim to co-express two different cysteine-rich plant defensins with antifungal properties, namely RsAFP2 and DmAMP1. The polyprotein precursor regions of these constructs all featured a leader peptide region from the DmAMP1 cDNA, the mature protein domain of DmAMP1, an internal propeptide region, and the mature protein domain of RsAFP2. Construct 3106 has a propeptide consisting of a part of the DmAMP1 propeptide and a putative subtilisin-like protease processing site (IGKR) at its C-terminus.

The rationale behind construct 3106, is based on our observations that the C-terminal propeptides of DmAMP1 are cleaved off at their N-terminus when expressed as DmAMP1-preproteins in tobacco, respectively, while this processing event does not prevent the

09763019.0749043
mature proteins from being sorted to the apoplast (De Bolle et al., 1996, Plant Mol. Biol. 31, 993-1008; R.W. Osborn and S. Attenborough, personal communication). This infers that the processing enzymes are either in the secretory pathway or in the apoplast. On the other hand, C-terminal cleavage of the internal propeptide in these constructs should be executed by a subtilisin-like protease, a member of which in yeast (Kex2) is known to occur in the Golgi apparatus (Wilcox C.A. and Fuller R.S., 1991, J. Cell. Biol. 115, 297-), while a member in tomato occurs in the apoplast (Tornero P. et al., 1997, J. Biol. Chem. 272, 14412-14419). Proteins deposited in the apoplast, the preferred deposition site for antimicrobial proteins engineered in transgenic plants (Jongedijk E. et al., 1995, Euphytica 85, 173-180; De Bolle et al., 1996, Plant Mol. Biol. 31, 993-1008) are normally synthesized via the secretory pathway, encompassing the Golgi apparatus.

Constructs were also made for expression of DmAMP1 (construct 3109, figure 6).

Expression levels of DmAMP1 and RsAFP2 were analysed in leaves taken from a series of T1 transgenic Arabidopsis plants resulting from transformation with the constructs described above. Most of the tested lines transformed with the polyprotein constructs 3106 clearly expressed both DmAMP1 and RsAFP2. There was generally a good correlation between DmAMP1 and RsAFP2 levels. However, the RsAFP2 levels were generally 2 to 5-fold lower than the DmAMP1 levels. It is not known whether the apparent lower expression levels of RsAFP2 versus DmAMP1 are real or whether they result from a bias in the extraction procedure or the assays. The expression levels in the lines transformed with the polyprotein constructs 3106 were generally much higher compared to those in lines transformed with the single protein construct 3109. Hence, the use of polyprotein constructs appears to result in enhanced expression, which is an unexpected finding.

Analysis of the proteins expressed for polyprotein constructs

A transgenic line was selected among each of the populations transformed with construct 3106 and the selected lines were further bred to obtain plants homozygous for the transgenes. In order to analyse whether DmAMP1 and RsAFP2 were correctly processed in these lines, extracts from the plants were prepared as described in Materials and Methods and separated by RP-HPLC on a C8-silica column. Fractions were collected and assessed for presence of compounds cross-reacting with antibodies raised against either DmAMP1 or RsAFP2 using Elisa assays.

DmAMP1 cross-reacting compound eluted at a position identical or very close to that of authentic DmAMP1 in the line transformed with construct 3106. Likewise, a RsAFP2 cross-reacting compound was detected in the 3106 lines at an elution position identical or very close to that of authentic RsAFP2. None of the fractions reacted with both the anti-DmAMP1 and anti-RsAFP2 antibodies, indicating that an uncleaved fusion protein was not present in the extracts. No cross-reacting compounds were observed in a non-transformed line.

It is concluded that the primary translation products of the transcription units of construct 3106 (partial DmAMP1 C-terminal propeptide with subtilisin-like protease site as a linker peptide) are somehow processed to yield separate DmAMP1-cross-reacting and RsAFP2-cross-reacting portions that appear to be identical or very closely related to DmAMP1 and RsAFP2, respectively, based on their chromatographic behavior.

Analysis of the subcellular location of coexpressed plant defensins

In order to determine whether the coexpressed plant defensins are either secreted extracellularly or deposited intracellularly, extracellular fluid and intracellular extract fractions were obtained from leaves of homozygous transgenic Arabidopsis lines transformed with constructs 3106. The cytosolic enzyme glucose-6-phosphate dehydrogenase was used as a marker to detect contamination of the extracellular fluid fraction with intracellular components. As shown in Table 1, glucose-6-phosphate dehydrogenase was partitioned in a ratio of about 80/20 between intracellular extract fractions and extracellular fluid fractions. In contrast, the majority of DmAMP1 and RsAFP2 content in all transgenic plants tested was found in the extracellular fluid fractions. These results indicate that both plant defensins released from the polyprotein precursors are deposited primarily in the apoplast. Hence, all processing steps that result in cleavage of the polyprotein structure must occur either in the apoplast or along the secretory pathway.

Table 1: Relative abundance of glucose-6-phosphate dehydrogenase activity (GPD), DmAMP1 and RsAFP2 in the extracellular fluid (EF) and intracellular extract (IE) fractions obtained from transgenic Arabidopsis plants.

Construct	Relative abundance ¹ (%) of					
	GPD		DmAMP1		RsAFP2	
	EF	IE	EF	IE	EF	IE
pFAJ3106	17	83	94	6	60	40

¹Relative abundance is expressed as % of the sum of the contents in the EF and IE fractions.

EXAMPLE 4

Expression of the sweet tasting protein Brazzein in tomato

Production of transgenic tomato plants with increased accumulation of sweet tasting protein Brazzein.

Constructs were prepared containing the Dahlia (*Dahlia merckii*) antimicrobial protein signal peptide fused with the Brazzein gene under the transcriptional control of the Arabidopsis polyubiquitin extension protein promoter (UBQ) or the Polygalacturonase promoter (PG). Constructs were also prepared which encoded Brazzein without a signal peptide but with an N-terminal methionine by the insertion of ATG nucleotides upstream of the Brazzein gene under the expressional control of either the UBQ promoter or the PG promoter. These were prepared as follows:

Construction of the transformation vector for expression in tomato with Dahlia signal peptide fused to Brazzein under the expressional control of either the UBQ promoter or the PG promoter:

A synthetic DNA was produced which coded for the Dahlia signal peptide fused to Brazzein. The codons were optimised for expression in tomato. Using appropriate restriction sites the coding sequence was cloned into a plasmid vector. The coding region was excised from the plasmid and cloned between the promoter in question and the terminator in the correct orientation for expression.

Generation and analysis of plants transformed with the transformation vector.

The vector was transferred to *Agrobacterium tumefaciens* LBA4404 (a microorganism widely available to plant biotechnologists) and used to transform tomato plants. Transformation of tomato stem segments followed standard protocols (e.g. Bird et al Plant Molecular Biology 11, 651-662, 1988). Transformed plants were identified by their ability to grow on media containing the antibiotic kanamycin. Up to 30 individual plants were regenerated with each construct and grown to maturity. The presence of the construct in all of the plants was confirmed by polymerase chain reaction analysis. DNA Southern blot analysis on all plants indicated that the insert copy number was between 1 and 10. Northern blot analysis on fruit from one plant indicated that the Brazzein gene was expressed.

Brazzein production in the fruit of all plants was measured by ELISA (enzyme linked immunoabsorption assay) using a polyclonal and a monoclonal antibody raised against native Brazzein protein isolated from the fruit of the plant *Pentadiplandra brazzeana* Baillon. Two fruit were collected from each transgenic plant at 7 days post breaker (the term breaker is used to indicate when the tomato fruit first show signs of the orange colouration characteristic of most mature tomato fruit). Total fruit protein was extracted from a sample of the pericarp of each of the fruit. The amount of Brazzein protein in the total protein extract was measured by ELISA and calculated as the amount of Brazzein per gram fresh weight of the fruit. For each plant the average Brazzein content of the two fruits was calculated. In some plants Brazzein could not be detected in the fruit using the ELISA technique. Western blot analysis of the total protein extract from some of the fruit revealed a 6.5kD protein band which matches the predicted size of the mature Brazzein protein. This confirmed that the fruit contained Brazzein and that the signal peptide had been cleaved as if the signal peptide had not been cleaved, one would expect the protein to be larger. The Brazzein in fruit from plants which had been transformed with a construct lacking a signal peptide was not detected by Western blot. This is because the Brazzein content in these fruit is below the level of detection by western blot. ELISA is a more sensitive technique than western blot and protein was detected in these fruit by this method.

The results are summarised in Table 2 below.

TABLE 2

Construct Name	Promoter	Signal Peptide	No. of Plants Tested	Plants expressing Brazzein
pZPS34	UBQ	None	29	18
pZPS35	UBQ	Dahlia AMP1	25	23
pZPS37	PG	None	15	7
pZPS38	PG	Dahlia AMP1	13	11

Table 2 (continued)

Construct Name	Max Brazzein ng/g Fresh wt	Min Brazzein ng/g Fresh wt	Mean Brazzein in those plants expressing the gene
pZPS34	25.57	Not Detected	6.85
pZPS35	226.53	Not Detected	43.89
pZPS37	12.77	Not Detected	3.32
pZPS38	51745.77	Not Detected	12867.34

Example 5Construction of Dm-AMP Transient Expression Vectors

To produce proteins for assessment of the relative activity of the variants of Dm-AMP, three vectors were constructed for transformation of black Mexican sweet (BMS) maize cell suspensions to give transient expression of Dm-AMPs.

The vector chosen for these experiments was pAID-MR7.

pAID-MR7 was constructed using the commercially available cloning vector pNEB193 (New England Biochemicals) itself a modified version of pUC19 (Yanisch-Perron C., Vieira J. and Messing J. "Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors." *Gene*; 33:103-19 (1985)). Gene components to facilitate protein expression were inserted within the multiple cloning region of pNEB193, namely:

- 1) A plant promoter to drive transcription, a 1.9Kb Xba I fragment of the MR7 promoter (MR7 prom.) from maize (as described in US Patent No. 5837848)
- 2) A sequence known to enhance gene transcription, the alcohol dehydrogenase intron 1 (I 1) from maize (Dennis E.S., Gerlach W.L., Pryor A.J., Bennetzen J.L., Inglis A., Llewellyn D., Sachs M.M., Ferl R.J. and Peacock W.J. "Molecular analysis of the alcohol dehydrogenase (Adh1) gene of maize." *Nucleic Acids Research*; 12:3983-4000(1984)).

- 3) A multiple cloning region for insertion of open reading frames containing the site for restriction endonuclease Xba I.
- 4) A 3' region for mRNA transcript termination and polyadenylation from the cauliflower mosaic virus 35S RNA transcript (3') (Pietrak et al Nucleic Acid Research 14 5857-5868 (1986), Franck A., Guilley H., Jonard G., Richards K. and Hirth L. "Nucleotide sequence of cauliflower mosaic virus DNA." Cell; 21: 285-94 (1980)).

To produce proteins for assessment of the relative activity of the variants of Dm-AMP, three vectors were constructed for use in a transient expression system.

All plasmid DNA described in the following examples was prepared using Promega Wizard mini-prep or Promega Wizard midi-prep kits using the manufacturer's suggested protocols. DNA sequencing was carried out using USB Sequenase kits and the manufacturer's suggested protocols.

Example 5a

Vector DNA was prepared by digesting plasmid DNA of pAIDMR7 with Xba I and the ends filled in with Klenow DNA polymerase. The linear vector was isolated from an agarose gel by electroelution and ethanol precipitation. The DNA pellet was air dried and taken up in a small volume of water.

Plasmid DNA of a cDNA clone containing a Dm2.1 ORF was digested with Eco RI and Sca I and the ends filled in with Klenow DNA polymerase. Insert DNA containing the Dm2.1 coding region was isolated from an agarose gel by electroelution and ethanol precipitation. The DNA pellet was air dried and taken up in a small volume of water.

Vector and insert DNA were ligated together using T4 DNA ligase and transformed into competent *E. coli* MC1022 cells. Transformation mixes were plated onto L-agar plates containing 100 µg/ml ampicillin and incubated at 37°C for 16 hours. Colonies were picked and cells shaken for 16 hours in 3 ml L-broth containing 100 µg/ml ampicillin at 37°C.

Plasmid DNA was prepared from several colonies and used in DNA sequencing reactions to identify transformants containing the Dm2.1 coding region in the appropriate orientation with respect to the MR7 promoter.

One such clone was identified and named pAIDMR721.

Example 5b

Vector DNA was prepared as in Example 5a.

Plasmid DNA of a cDNA clone containing a Dm2.3 ORF was digested with Eco RI and Sca I and the ends filled in with Klenow DNA polymerase. Insert DNA containing the Dm2.3 coding region was isolated from an agarose gel by electroelution and ethanol precipitation. The DNA pellet was air dried and taken up in a small volume of water.

Vector and insert DNA were ligated together, transformed into *E. coli* MC1022 and colonies characterised by DNA sequencing as described in Example 5a. A clone was identified containing the Dm2.3 ORF in the desired orientation and named pAIDMR723.

Example 5c

Vector DNA was prepared as in Example 5a.

Plasmid DNA of a cDNA clone containing a Dm2.5 ORF was digested with Eco RI and Dra I and the ends filled in with Klenow DNA polymerase. Insert DNA containing the Dm2.5 coding region was isolated from an agarose gel by electroelution and ethanol precipitation. The DNA pellet was air dried and taken up in a small volume of water.

Vector and insert DNA were ligated together, transformed into *E. coli* MC1022 and colonies characterised by DNA sequencing as described in Example 5a. A clone was identified containing the Dm2.5 ORF in the desired orientation and named pAIDMR725.

Example 6

Transient Expression of Dm-AMPs

Plasmid DNA of clones pAIDMR721 pAIDMR723, pAIDMR725 and pAIDMR7 is used to transform cultured maize BMS cells using the PEG method.

Protoplast preparation and transformation

Protoplasts are isolated from a maize suspension of Black Mexican Sweet Corn suspension culture (BMS) [Green, Hort. Sci., 12 (1977) 131; Smith et al., Plant Sci. Lett., 36 (1984) 67] subcultured in BMS medium (MS medium supplemented with 2% sucrose, 2 mg/l 2,4-D, pH5.8). Cells from suspensions two days post subculture are digested in enzyme mixture (2.0% cellulase RS (Yakult Honsha Co., Ltd), 0.2% pectolyase Y23 (Yakult Honsha Co., Ltd), 0.5M mannitol, 5mM CaCl₂·2H₂O, 0.5% MES, pH5.6, ~660mmol/kg) using ~10ml/g

cells, incubating at 25°C, rotating gently for 2 hours. The digestion mixture is sieved through 250µm and 38µm sieves, and the filtrate centrifuged at 700rpm for 3.5 minutes. Protoplasts are resuspended in wash buffer (0.358M KCl, 1.0mM NH₄NO₃, 5.0mM CaCl₂·2H₂O, 0.5mM KH₂PO₄, pH4.8, ~670mmol/kg) and pelleted twice prior to resuspending in wash buffer and counting. Transformation is achieved using PEG (PEG 3350, Sigma Co) mediated uptake (Negrutiu et al., 1987) employing plasmid DNA prepared using Qiagen midi plasmid preparation kit (Qiagen Ltd, Crawley, UK). Protoplasts are resuspended at 2 x 10⁶/ml in MaMg medium (0.4M mannitol, 15mM MgCl₂, 0.1% MES, pH5.6, ~450mmol/kg) aliquotting 0.5ml / treatment (i.e. 1x10⁶ protoplasts/treatment). Samples are heat shocked at 45°C for 5 minutes then cooled to room temperature. Each transformation is carried out with 10µg of pAID-MR7 alone or 10µg of each construct pAIDMR721, pAIDMR723 or pAIDMR725. Each protoplast treatment is resuspended in 1.5ml culture medium (MS medium, 2% sucrose, 2mg/l 2,4-D, 9% mannitol, pH5.6, ~700mmol/kg). Samples are incubated in 3cm dishes at 25°C, in the dark, for 48 hours prior to harvesting.

After 48 hours incubation cells are separated from media by centrifugation.

Cells are osmotically lysed by the addition of water. Cell debris is pelleted by centrifugation and the proteins remaining in solution are freeze dried. The freeze dried proteins are taken up in a small volume of water and the concentration of protein determined using Bradford reagent.

Culture media removed from cells is freeze dried and taken up in a small volume of water, the concentration of protein is determined as above.

Protein samples isolated from all BMS transformations are assayed for spore germination inhibition in a bioassay against *Fusarium culmorum* spores as described in Published International Patent Application No. WO 93/05153.

CLAIMS

1. A polynucleotide comprising a sequence selected from those depicted in
SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4 and SEQ ID No. 5.
2. A polynucleotide sequence comprising a sequence selected from the group consisting
of nucleotides 53 to 385 in SEQ ID No. 1, nucleotides 11 to 334 in SEQ ID No. 2,
nucleotides 24 to 317 in SEQ ID No. 3, nucleotides 20 to 343 in SEQ ID No. 4 or
nucleotides 1 to 446 in SEQ ID No. 5.
3. A polynucleotide sequence comprising a sequence selected from the group consisting
of nucleotides 137 to 286 in SEQ ID No. 1, nucleotides 95 to 244 in SEQ ID No. 2,
nucleotides 108 to 257 in SEQ ID No. 3, nucleotides 104 to 253 in SEQ ID No. 4 or
nucleotides 177 to 326 in SEQ ID No. 5.
4. A polynucleotide sequence comprising a sequence selected from the group consisting
of nucleotides 287 to 385 in SEQ ID NO. 1, nucleotides 245 to 334 in SEQ ID No. 2,
nucleotides 258 to 317 in SEQ ID No. 3, nucleotides 254 to 343 in SEQ ID No. 4 or
nucleotides 327 to 446 in SEQ ID No.5.
5. A polynucleotide encoding a protein having a substantially similar activity to that
encoded by any of SEQ ID No. 1, No 2, No. 3, No,4 or No. 5 which polynucleotide
is complementary to one which when incubated at a temperature of between 55 and
65°C in a solution containing 5 X SSC (saline sodium citrate buffer) containing 0.1%
SDS and 0.25% powdered skimmed milk followed by washing at the same
temperature with 0.1, 0.5 or 2x SSC containing 0.1% SDS still hybridises with a
sequence depicted in SEQ ID No 1, SEQ ID No 2, SEQ ID No3, SEQ ID No.4 or
SEQ ID No.5 with the proviso that the sequence is not that described in SEQ ID No.6
or 7.

6. A polynucleotide encoding a protein having a substantially similar activity to that encoded by nucleotides 137 to 286 in SEQ ID No. 1, nucleotides 95 to 244 in SEQ ID No. 2, nucleotides 108 to 257 in SEQ ID No. 3, nucleotides 104 to 253 in SEQ ID No. 4 or nucleotides 177 to 326 in SEQ ID No. 5., which polynucleotide is complementary to one which when incubated at a temperature of between 55 and 65°C in a solution containing 5 X SSC (saline sodium citrate buffer) containing 0.1% SDS and 0.25% powdered skimmed milk followed by washing at the same temperature with 0.1, 0.5 or 2x SSC containing 0.1% SDS still hybridises with a sequence depicted by nucleotides 137 to 286 in SEQ ID No. 1, by nucleotides 95 to 244 in SEQ ID No. 2, by nucleotides 108 to 257 in SEQ ID No. 3, by nucleotides 104 to 253 in SEQ ID No. 4 or by nucleotides 177 to 326 in SEQ ID No. 5. with the proviso that said sequence is not that described in SEQ ID No. 6 or SEQ ID No. 7.
7. A polynucleotide according to any preceding claim, further comprising a region encoding a peptide which is capable of targeting the translation products of the sequence to plastids such as chloroplasts, mitochondria, other organelles or plant cell walls.
8. A polynucleotide according to any preceding claim, wherein translational enhancing sequences are inserted 5' of the protein encoding regions comprised by the polynucleotide.
9. A polynucleotide according to any preceding claim, which is modified in that mRNA instability motifs and/or fortuitous splice regions are removed, or plant preferred codons are used so that expression of the thus modified polynucleotide in a plant yields substantially similar protein having a substantially similar activity/function to that obtained by expression of the unmodified polynucleotide in the organism in which the protein encoding regions of the unmodified polynucleotide are endogenous, with the proviso that if the thus modified polynucleotide comprises plant preferred codons, the degree of identity between the modified polynucleotide and a

polynucleotide endogenously contained within the said plant and encoding substantially the same protein is less than about 60%.

10. A plant transformation vector comprising a plant operable promoter, a polynucleotide sequence according to any of the preceding claims under the transcriptional control thereof and a plant transcription terminator.
11. Plant tissue transformed with the polynucleotide of any one of claims 1 to 9 or the vector of claim 10 and material derived from the said transformed plant tissue.
12. Morphologically normal fertile whole plants comprising the tissue or material of the preceding claim.
13. The progeny of the plants of the preceding claim, which progeny comprises the polynucleotide of any one of claims 1 to 9 stably incorporated into its genome and heritable in a mendelian manner, the seeds of such plants and such progeny.
14. A method of producing plants which are substantially tolerant or substantially resistant to microbial infection, comprising the steps of:
 - (i) transforming plant material with the polynucleotide of any one of claims 1 to 9 or the vector of claim 10
 - (ii) selecting the thus transformed material; and
 - (iii) regenerating the thus selected material into morphologically normal fertile whole plants.
15. Use of the polynucleotide of any one of claims 1 to 9, or the vector of claim 10 in the production of plant tissues and/or morphologically normal fertile whole plants which are substantially tolerant or substantially resistant to microbial infection.
16. The translation product of the region comprised by nucleotides 137 to 286 in SEQ ID No. 1.; nucleotides 95 to 244 in SEQ ID No.2, nucleotides 108 to 257 in SEQ ID No.

3, or nucleotides 104 to 253 in SEQ ID No. 4 and protein having an amino acid sequence which is at least 95% similar to said product.

- 5 17. The translation product of the region comprised by nucleotides 287 to 385 in SEQ ID NO. 1, nucleotides 245 to 334 in SEQ ID No. 2, nucleotides 258 to 317 in SEQ ID No. 3, nucleotides 254 to 343 in SEQ ID No. 4 or nucleotides 327 to 446 in SEQ ID No.5 and protein having an amino acid sequence which is at least 85% similar to said product.
- 10 18. A method of selectively controlling microorganisms at a locus comprising the plants, progeny and/or seeds of either of claims 12 or 13, comprising applying to the locus a microorganism controlling amount of the translation product of the region comprised by nucleotides 137 to 286 in SEQ ID No. 1.; nucleotides 95 to 244 in SEQ ID No.2, nucleotides 108 to 257 in SEQ ID No. 3, or nucleotides 104 to 253 in SEQ ID No. 4.
- 15 19. Use of the polynucleotide of any one of claims 1 to 9, or the vector of claim 10 in the production of an antimicrobial protein.

Dm Gene Structure Sequence ID No. 5 Fig.1A.

```
      M V N R S V A F S A F V L I L F V L A I
1  ATGGTGAATCGGTCGGTTCGTTCTCCGGTTCGTTCTGATCCTTTTCGTGCTCGCCATC

      S
61  TCAGGTTATCAAACTTTAGTTCAATTTATTGAATATGATAGTATTATATCTTTATGG
      intron
      D I A S V S G E
121  TTTTATGTGTTCTGACAAGTTGCAAAATATTGAGTAGATATCGCATCCGTTAGTGGAGAAC

      L C E K A S K T W S G N C G N T G H C D
181  TATCGGAGAAAGCTAGCAAGACATGGTCGGGAAACTGTGGCAATACGGGACATTGTGACA

      N Q C K S W E G A A H G A C H V R N G K
      NcoI
241  ACCAATGTAAATCATGGGAGGGTGGCGCCCATGGAGCGTGTCAATGCGTAACGGGAAAC

      H M C F C Y F N C K K A E K L A Q D K L
      HindIII
301  ACATGTGTTTCTGTACTTCAATTGTAAAAAGCCGAAAAGCTTGCTCAAGACAACTTA

      K A E Q L A Q D K L N A Q K L D R D A K
      HindIII
361  AAGCCGAACAACCTCGCTCAAGACAACTTAATGCCCAAAAGCTTGACCGTGATGCCAAGA

      K V V P N V E H P
421  AAGTGTTCCTCCAAACGTTGAACATCCG
```

Dm2.18 Sequence ID No. 1 Fig.1B.

1 GTGCCCCGGGTCACGAAGTTCGGCACATCTTAGCGTTATGCATAAGTCAAAATGGCCAA M A K

61 AAATTCAGTTGCTTTCTTTGCATTGTCCTGCTTCTTTTCATTCTTGTCTATCTCAGAAAT

121 CAGATCGGTGAAGGGGAATTATGTGAGAAGGCAAGACATGGTCTGGAAATTGTGG

181 CAATACAAGACACTGTGATGACCAGTGCAAGTCTTGGAGGGTGCAGCCCATGGAGCTTG

241 TCACGTGCCGGTGGAAACACACATGTGCTTCTGCTACTTCAACTGTCCCAAGCCACAGAA

301 GTTGGCTGAGGATAAACTCAGAGCAGCAGAGCTAGCAAGGAGAGAATAATATTGGAGC

361 TGAAAAGGTGCCTTCAGCCACACCTTGAGTACTAACAAA E K V P S A T P

3/19

Dm 2.1 Sequence ID No. 2 Fig.2A.

1 GGCACGAGTAATGGCCAAAATTCAAGTTCCTTCTTAGCATTTCTTCTGCTTCTTTTCGT
M A K N S V A F L A F L L L L F V
61 TCTTGCTATCTCAGAAATCGGATCGGTGAAGGGGAATTATGTGAGAAAGGCAAGCAAGAC
L A I S E I G S V K G E L C E K A S K T
121 ATGGTCTGAAATTGTGGCAATACAAGACACTGTGATGACCAGTGCAAGTCTTGGGAGGG
W S G N C G N T R H C D D Q C K S W E G
181 CGCAGCCCATGGAGCTTGTACGTCCGGTGGGAAACACATGTGCTTTTGCTACTTCAA
A A H G A C H V R G G K H M C F C Y F N
241 CTGTTCCAAAGCCAGAAGCTGGCTCAGGATAAACTCAAAGCCGACAAGCTCGCCAAGGA
C S K A Q K L A Q D K L K A D K L A K E
K S E A E K V P A T P
301 GAAGAGTGAAGCCGAAAAGGTGCCAGCTACACCTTGAGTACTAAACAAGTTGTATGATT
GAAGATAAAGAGAAAATGCTTCTTAGTTACCATATTTAGCATTTCTCTAATGTGTAATGTT
361 TGTGCTTTTGGAACTAATTGCTTAACTATGATTCAGCTAATAATGTTTAAAGTATATA
421 ATATAAGTTATCTTATTTGAAGCCTGTAAAAAATAAAAAA
481 ATATAAGTTATCTTATTTGAAGCCTGTAAAAAATAAAAAA



SUBSTITUTE SHEET (RULE 26)

Dm2.5 Sequence ID No. 4 Fig.3.

1 GGCACGAGCCTATTAAAAAATGGTGAATCGATCGGTGCTTCTCCGTGTTCTGAT
M V N R S V A F S V F V L I
L F V L A I S D I T S V R G E V C E K A
61 CCTTTTCGTGCTGCCATCTCAGATATACAAAGTGTGAGAGGAGAAGTATGCGAGAAAGC
S K T W S G N C G N T G H C D N Q C K Y
121 TAGCAAGACATGGTCAGGAACTGTGGCAACACGGGACACTGTGACAAACCAATGTAAATA
W E G A A H G A C H V R G G K H M C F C
181 CTGGAGGGGGCGCCCATGGGGCTGCCACGTGCGTGGAGGGAACACATGTGTTCTG
Y F K C P K A E K L A Q D K V N A Q E L
241 CTACTTCAAGTGCCCCAAGCCGAAAGCTTGCTCAAGACAAAGTTAATGCCCCAAGAGCT
D R D A K K V I P N V E H P
301 TGACCGTGATGCCAAGAAAGTGATTCGGAACGTTGAACATCCGTGAAAGGGTCGGTTTCT
TAAATAGAAAGCTTAGATTACGAATCGAATAACTATAGAAAATGTTGCTAAATGTC
361 ACATTATAATTAGAACTTTATGATTGTGTCAATAGGGCATTTTCTTGTAGTATATGT
421 GTAATAAGGTGATGCTTTTATGCTTTTCGTGCGTAAGAGTTTTCGACTATGTGTAATAAA
541 GAAAGGCTTTTTTTTTTAAAAAATAAAAAAAAAA


6/19


Fig.4.



7/19

Fig.4 (Cont).





Symbols

RB: right border of T-DNA

Tnos: terminator of T-DNA nopaline synthase gene

MP Rs-AFP2: mature protein domain of Rs-AFP2

LP: first 16 AA of Dm-AMP1 C-terminal propeptide and subtilisin-like protease recognition site IGKR

MP Dm-AMP1: mature protein domain of Dm-AMP1 cDNA

SP Dm-AMP1: signal peptide domain of Dm-AMP1 cDNA

TMV: tobacco mosaic virus 5' leader sequence

Penh35S: promotor of 35S RNA of cauliflower mosaic virus with duplicated enhancer region

Pnos: promotor of T-DNA nopaline synthase gene

bar: basta resistance encoding gene

Tg7: terminator of T-DNA gene 7

LB: left border of T-DNA

*: unique restriction site

9/19




Fig.6.

Symbols

- RB: right border of T-DNA
 Tnos: terminator of T-DNA nopaline synthase gene
 MP Dm-AMP1: mature protein domain of Dm-AMP1
 SP Dm-AMP1: signal peptide domain of Dm-AMP1 cDNA
 TMV: tobacco mosaic virus 5' leader sequence
 Penh35S: promotor of 35S RNA of cauliflower mosaic virus with duplicated enhancer region
 Pnos: promotor of T-DNA nopaline synthase gene
 bar: basta resistance encoding gene
 Tg7: terminator of T-DNA gene 7
 LB: left border of T-DNA
 *: unique restriction site

pFAJ3106

Fig.7.

XhoI

CTCGAGTATTTTACAAACAATTACCAACAACAACAACAACAACAACAACAATTACATTTACT

NcoI

ATTTACAAATTACACCATGGTGAATCGGTGCGTTGCGTTCTCCGCGTTCTCGTTCTGATCCIT
M V N R S V A F S A F V L I L

TTCGTGCTCGCCATCTCAGATATCGCATCCGTTAGTGGAGAACTATGCGAGAAAGCTAGC
F V L A I S D I A S V S G E L C E K A S

AAGACGTGTCGGGCAACTGTGGCAACACGGGACATGTGTGACAACCAATGTAAATCATGG
K T W S G N C G N T G H C D N Q C K S W

GAGGTGCGGCCCATGGAGCGTGTGTCATGTGCGTAACGGGAAACACATGTGTTTCTGTTAC
E G A A H G A C H V R N G K H M C F C Y

TTCAATTGTAAAAAAGCCGAAAAGCTTGCTCAAGACAAACTTAAAGCCGAACAACATCATC
F N C K K A E K L A Q D K L K A E Q L I

GGAAAGAGGCAGAAGTTGTGCCAAAGGCCAAGTGGGACATGGTTCAGGAGTCTGTGGAAC
G K R Q K L C Q R P S G T W S G V C G N

AATAACGCATGCAAGAAATCAGTGCATTAGACTTGAGAAAGCACGACATGGATCTTGCAAC
N N A C K N Q C I R L E K A R H G S C N

SacI

TATGTCTTCCCAGCTCACAAGTGTATCTGCTACTTTCCTTGTGTTAATAGGAGCTC
Y V F P A H K C I C Y F P C

11/19

Fig.8.

pFAJ3109XhoI

CTCGAGTATTTTACAAACAATTACCAACAACAACAACAACAACAATTACAATTACT

NcoI

ATTTACAATTACACCATGGTGAATCGGTCGGTTGCGTTCTCCGCGTTCTCGTTCTGATCCTT

M V N R S V A F S A F V L I L

TTCGTGCTCGCCATCTCAGATATCGCATCCGTTAGTGGAGAACTATGCGAGAAAGCTAGC

F V L A I S D I A S V S G E L C E K A S

AAGACGTGGTCGGGCAACTGTGGCAACACGGGACATGTGACAACCAATGTAAATCATGG

K T W S G N C G N T G H C D N Q C K S W

GAGGTGCGGCCCATGGAGCGTGTCAATGTGCGTAATGGGAAACACATGTGTTTCTGTTAC

E G A A H G A C H V R N G K H M C F C Y


SacI

TTCAATTGTTGAGCTC

F N C -


12/19

Fig.9.



13/19


Fig.10.




14/19

WO 00/11196


Fig.11.






16/19

Fig.13.



Structure of DmAMP1 Gene and position of vector construction oligonucleotides





PCR Dahlia genomic DNA with DMVEC-1 and DMVEC-2, isolate 450 bp product.

PCR 450 bp DMVEC-1/DMVEC-2 PCR product with DMVEC 1 and 4.

Isolate 60 bp NcoI / SacI fragment, clone into pMJB1 NcoI / SacI=pDmAMPA.



Cut 450 bp DMVEC-1/DMVEC-2 PCR product NcoI / SacI . Isolate 180 bp NcoI / SacI fragment, clone into pMJB1 NcoI / SacI =pDmAMPB



PCR 450 bp DMVEC-1/DMVEC-2 PCR product with DMVEC 3 and 4.

Isolate 150 bp NcoI fragment, clone into pDmAMPA

and pDmAMPB NcoI =pDmAMPD and pDmAMPE



17/19


Fig.14.

Sequence ID No.6 Dm-AMP1	GAG CTT TGC GAG AAG GCT TCT AAG ACT TGG TCT GGA AAC
	TGG GAG GGA GCT GCT CAT GGA GCT TGC CAT GTT AGA AAC
Sequence ID No.7 Dm-AMP2	GAG GTT TGC GAG AAG GCT TCT AAG ACT TGG TCT GGA AAC

Fig.14 (Cont).

TGC GGA AAC ACT GGA CAT TGC GAT AAC CAA TGC AAG TCT
GGA AAG CAT ATG TGC TTC TGC TAC TTC AAC TGC
TGC GGA AAC ACT GGA CAT TGC

Fig.15.



Docket No.
PPD 50355/UST

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

POLYNUCLEOTIDE SEQUENCES

the specification of which

_____ is attached hereto
 X was filed on 17th August 1999 as PCT International Application Number
PCT/GB99/02720 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Claimed

Number	Country	Filing Date	Yes	No
9818003.7	United Kingdom	18 th August 1998	X	

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT International Application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application.

Application Number	Filing Date	Status

09763019 " 071901

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:


Thomas R. Savitsky, Reg. No. 31,661; Dianne Burkhard, Reg. No. P41,650;
Liza D. Hohenschutz, Reg. No. 33,712; William E. Dickheiser, Reg. No. 30,169.

Address all telephone calls to at telephone number (302)886-

Address all correspondence to: ZENECA Ag Products
Intellectual Property Department
1800 Concord Pike
P.O. Box 15458
Wilmington, DE 19850-5458

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor (given name, family name) ¹⁻⁰⁰ Ian Jeffrey EVANS

Inventor's signature 

Date 27 FEBRUARY 2001

Residence Bracknell, United Kingdom

British

GBX

Post Office Address Zeneca Limited, Jealott's Hill International Research Centre, Bracknell, Berkshire, RG42 6ET, United Kingdom

Full name of second inventor, if any (given name, family name) ²⁻⁰⁰ John Anthony RAY

Inventor's signature 

Date 27 FEBRUARY 2001

Residence Bracknell, United Kingdom

British

GBX

Post Office Address Zeneca Limited, Jealott's Hill International Research Centre, Bracknell, Berkshire, RG42 6ET, United Kingdom

09763019 071901
106720 67069260

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Evans, et al.

Serial No.: 09/763,019

Filed: Filing Receipt Not Received

Entitled: Polynucleotide Sequences

Attorney Docket No.: SYN-072

Examiner: TBA

Group Art Unit: TBA

Director of Patents
Washington, D.C. 20231

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed Director of Patents, Washington, D.C. 20231 on the date indicated below.

Date: July 19, 2001

Patricia Corrigan
Patricia Corrigan

ASSOCIATE POWER OF ATTORNEY (37 C.F.R. §1.34)

Sir or Madam:

Please recognize each of the following as an Associate Attorney in this case.

Scott M. Alter	<u>32,879</u>	Wayne A. Keown, Ph.D.	<u>33,923</u>
Hollie L. Baker	<u>31,321</u>	Ann-Louise Kerner, Ph.D.	<u>33,523</u>
Barbara A. Barakat	<u>32,190</u>	Janice M. Klunder, Ph.D.	<u>41,121</u>
Steven D. Barrett	<u>40,903</u>	James B. Lampert	<u>24,564</u>
Michael J. Bevilacqua	<u>31,091</u>	Keum J. Park	<u>42,059</u>
Nancy Chiu, Ph.D.	<u>43,545</u>	Jason A. Reyes	<u>41,513</u>
Michael A. Diener	<u>37,122</u>	Gretchen A. Rice, Ph.D.	<u>37,429</u>
Peter M. Dichiaro	<u>38,005</u>	Donald R. Steinberg	<u>37,241</u>
Richard A. Goldenberg	<u>38,895</u>	Colleen Superko	<u>39,850</u>
Edward D. Grieff	<u>38,898</u>	Hall C. Swaim	<u>22,838</u>
Sally Byrne	<u>40,545</u>	Rajesh Vallabh	<u>35,761</u>
Wayne M. Kennard	<u>30,271</u>	Henry N. Wixon	<u>32,073</u>
David J. Cerveney	<u>44,600</u>	Ayla A. Lari	<u>43,739</u>
Nels Lippert	<u>25,888</u>	Dominic Massa	<u>44,905</u>
Gregory S. Discher	<u>42,488</u>	Irah H. Donner	<u>35,120</u>


Robert McIssac	P46,918	Luke Yeh	43,296
David Cerveney	44,600	David Cavanaugh	36,476
Irah H. Donner	35,120	Gregory S. Discher	42,488
Anthony Kahng	42,704	Maria Maebius	42,967
Cynthia Nicholson	36,880	Tamara Pertmer	P4,856
MaryRose Scozzafava	36,268	Victor Souto	33,458
Leonid Thenor	39,397	Michael J. Twomey	38,349
Gary A. Walpert	26,098	Lisa Wilson	34,045

Address: Hale and Dorr LLP
60 State Street
Boston, MA 02109
Tel.: 617-526-6000
Fax: 617-526-5000

Kindly note that the Attorney Docket Number has changed to SYN-072.

Respectfully submitted,

Date: July 13, 2001


William E. Dickheiser
Reg. No. 30,169
Attorney of Record

Syngenta Crop Protection
2 Righter Parkway
P.O. Box 15458
Wilmington, DE 19850-5458
Tel: 302-476-2092
Fax: 302-476-2022

teresa bence - h:\corrigan_patricia\legal\syngenta\syn-072\ptodocs\assoc poa.doc

09/20/01 09:20:20

Rec'd PCT/PTO 19 JUL 2001

09/763,019

PTO/SB/122 (10-00)

Approved for use through 10/31/2002. OMB 0651-0035

Please type a plus sign (+) inside this box ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CHANGE OF CORRESPONDENCE ADDRESS Application

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

Application Number	09/763,019
Filing Date	Filing Receipt Not Recv'd
First Named Inventor	Evans
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	SYN-072

Please change the Correspondence Address for the above-identified application to:



Customer Number

23483

Type Customer Number here

Place Customer
Number Bar Code
Label here

OR



Firm or
Individual Name

Hale and Dorr LLP

Address

60 State Street

Address

City

Boston

State

MA

ZIP

02109

Country

USA

Telephone

617-526-6000

Fax

617-526-5000

This form cannot be used to change the data associated with a Customer Number. To change the data associated with an existing Customer Number use "Request for Customer Number Data Change" (PTO/SB/124).

I am the :



Applicant/Inventor.



Assignee of record of the entire interest.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).



Attorney or Agent of record.



Registered practitioner named in the application transmittal letter in an application without an executed oath or declaration. See 37 CFR 1.33(a)(1). Registration Number _____

Typed or Printed
Name

Colleen Superko, Reg. No. 39,850

Signature

Colleen Superko

Date

July 19, 2001

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.



*Total of _____ forms are submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

106720 6706360

SEQUENCE LISTING

<110> ZENECA Limited

Evans, Ian J

Ray, John A

<120> Polynucleotide sequences

<130> PPD 50355

<140>

<141>

<150> GB 9818003.7

<151> 1998-08-18

<160> 37

<170> PatentIn Ver. 2.1

<210> 1

<211> 399

<212> DNA

<213> Dahlia merckii

<220>

<221> CDS

<222> (53)..(388)

<400> 1

gtgccccggg tcacgaagtt cggcacatct tagcgttatg cataagtcaa aa atg gcc 58

Met Ala

1

aaa aat tca gtt gct ttc ttt gca ttg tgc ctg ctt ctt ttc att ctt 106

Lys Asn Ser Val Ala Phe Phe Ala Leu Cys Leu Leu Leu Phe Ile Leu

5

10

15

2

```

gct atc tca gaa atc aga tcg gtg aag ggg gaa tta tgt gag aag gca 154
Ala Ile Ser Glu Ile Arg Ser Val Lys Gly Glu Leu Cys Glu Lys Ala
      20                25                30

agc aag aca tgg tct gga aat tgt ggc aat aca aga cac tgt gat gac 202
Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Arg His Cys Asp Asp
      35                40                45                50

cag tgc aag tct tgg gag ggt gca gcc cat gga gct tgt cac gtg cgc 250
Gln Cys Lys Ser Trp Glu Gly Ala Ala His Gly Ala Cys His Val Arg
              55                60                65

ggt ggg aaa cac atg tgc ttc tgc tac ttc aac tgt ccc aaa gcc cag 298
Gly Gly Lys His Met Cys Phe Cys Tyr Phe Asn Cys Pro Lys Ala Gln
              70                75                80

aag ttg gct gag gat aaa ctc aga gca gca gag cta gca aag gag aag 346
Lys Leu Ala Glu Asp Lys Leu Arg Ala Ala Glu Leu Ala Lys Glu Lys
              85                90                95

aat aat att gga gct gaa aag gtg cct tca gcc aca cct tga 388
Asn Asn Ile Gly Ala Glu Lys Val Pro Ser Ala Thr Pro
      100                105                110

gtactaacaa a 399

```

<210> 2

<211> 523

<212> DNA

<213> Dahlia merckii

<220>

<221> CDS

<222> (11)..(337)

<400> 2

ggcacgagta atg gcc aaa aat tca gtt gct ttc tta gca ttt ctt ctg 49

Met Ala Lys Asn Ser Val Ala Phe Leu Ala Phe Leu Leu

1

5

10

ctt ctt ttc gtt ctt gct atc tca gaa atc gga tcg gtg aag ggg gaa 97

Leu Leu Phe Val Leu Ala Ile Ser Glu Ile Gly Ser Val Lys Gly Glu

15

20

25

tta tgt gag aag gca agc aag aca tgg tct gga aat tgt ggc aat aca 145

Leu Cys Glu Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr

30

35

40

45

aga cac tgt gat gac cag tgc aag tct tgg gag ggc gca gcc cat gga 193

Arg His Cys Asp Asp Gln Cys Lys Ser Trp Glu Gly Ala Ala His Gly

50

55

60

gct tgt cac gtg cgc ggt ggg aaa cac atg tgc ttt tgc tac ttc aac 241

Ala Cys His Val Arg Gly Gly Lys His Met Cys Phe Cys Tyr Phe Asn

65

70

75

tgt tcc aaa gcc cag aag ctg gct cag gat aaa ctc aaa gcc gac aag 289

Cys Ser Lys Ala Gln Lys Leu Ala Gln Asp Lys Leu Lys Ala Asp Lys

80

85

90

ctc gcc aag gag aag agt gaa gcc gaa aag gtg cca gct aca cct tga 337

Leu Ala Lys Glu Lys Ser Glu Ala Glu Lys Val Pro Ala Thr Pro

95

100

105

gtactaacia gtgttgatg attatgaata aagagaaaat gctttctagt taccatattt 397

agcattctct aatgtgtaat gtttggtgct tttggaacta attgcttaac tatgattcca 457

gctaataatg ttttaagtat ataataaag ttatcttatt ttgaagcctg taaaaaaaaa 517

aaaaaa

523

P05T20 6T0E260

<210> 3

<211> 385

<212> DNA

<213> Dahlia merckii

<220>

<221> CDS

<222> (24)..(320)

<400> 3

cggcacgagg cacaatctca aaa atg gcc aaa aat tcg gtt gct ttc ttt gca 53

Met Ala Lys Asn Ser Val Ala Phe Phe Ala

1 5 10

ttt gtc ctg ctt ctt ttc gtt ctt gct atc tca gaa att gga tcg gtg 101

Phe Val Leu Leu Leu Phe Val Leu Ala Ile Ser Glu Ile Gly Ser Val

15 20 25

aag gga gaa tta tgt gag aag gca agc aag aca tgg tct gga aat tgt 149

Lys Gly Glu Leu Cys Glu Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys

30 35 40

ggc atc aca tca cac tgt gac aac cag tgc cgg tcg tgg gag ggt gca 197

Gly Ile Thr Ser His Cys Asp Asn Gln Cys Arg Ser Trp Glu Gly Ala

45 50 55

atc cat gga gct tgt cac gtg cgc ggt ggg aaa cac atg tgc ttc tgc 245

Ile His Gly Ala Cys His Val Arg Gly Gly Lys His Met Cys Phe Cys

60 65 70

tac ttc aac tgt tcc aaa gcc gat gag ctc gcg aag gag aag att gaa 293

Tyr Phe Asn Cys Ser Lys Ala Asp Glu Leu Ala Lys Glu Lys Ile Glu

75 80 85 90

gcc gaa aag atg cca gcc aca cct tga gtactaacaa atgctatatg 340

Ala Glu Lys Met Pro Ala Thr Pro

95

T06720"57039/604

attataaata aagagaaaat gctttctaaa aaaaaaaaaa aaaaa

385

<210> 4

<211> 577

<212> DNA

<213> Dahlia merckii

<220>

<221> CDS

<222> (20)..(346)

<400> 4

ggcagagacc tattaaaaa atg gtg aat cga tcg gtt gct ttc tcc gtg ttc 52

Met Val Asn Arg Ser Val Ala Phe Ser Val Phe

1

5

10

gtt ctg atc ctt ttc gtg ctc gcc atc tca gat atc aca agt gtg aga 100

Val Leu Ile Leu Phe Val Leu Ala Ile Ser Asp Ile Thr Ser Val Arg

15

20

25

gga gaa gta tgc gag aaa gct agc aag aca tgg tca gga aac tgt ggc 148

Gly Glu Val Cys Glu Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly

30

35

40

aac acg gga cac tgt gac aac caa tgt aaa tac tgg gag ggg gcg gcc 196

Asn Thr Gly His Cys Asp Asn Gln Cys Lys Tyr Trp Glu Gly Ala Ala

45

50

55

cat ggg gcg tgc cac gtg cgt gga ggg aaa cac atg tgt ttc tgc tac 244

His Gly Ala Cys His Val Arg Gly Gly Lys His Met Cys Phe Cys Tyr

60

65

70

75

ttc aag tgt ccc aaa gcc gaa aag ctt gct caa gac aaa gtt aat gcc 292

Phe Lys Cys Pro Lys Ala Glu Lys Leu Ala Gln Asp Lys Val Asn Ala

80

85

90

6

caa gag ctt gac cgt gat gcc aag aaa gtg att ccg aac gtt gaa cat 340
 Gln Glu Leu Asp Arg Asp Ala Lys Lys Val Ile Pro Asn Val Glu His
 95 100 105

ccg tga aagggtcggg ttcttttaaat agaaagtctt agattacgaa tgcgaataac 396
 Pro

tatagaaaat gtttgctaaa tgtcacatta taattagaac tttatgattg ttgtcaatag 456

ggcattttct tgtagtgat atgtgtaata aggtgatgct tttatgcttt tcgtgcgtaa 516

gagttttcga ctatgtgtaa taaagaaagg gtcttttttt tttaaaaaaa aaaaaaaaaa 576

a 577

<210> 5

<211> 446

<212> DNA

<213> Dahlia merckii

<220>

<221> CDS

<222> (1)..(64)

<220>

<221> CDS

<222> (157)..(446)

<400> 5

atg gtg aat cgg tcg gtt gcg ttc tcc gcg ttc gtt ctg atc ctt ttc 48
 Met Val Asn Arg Ser Val Ala Phe Ser Ala Phe Val Leu Ile Leu Phe
 1 5 10 15

gtg ctc gcc atc tca g gttatcaaat ctttagttca tttattgaat atgatagtat 104
 Val Leu Ala Ile Ser

20

PCT/GB99/02720

ttatatattcatt ttatgggtttt atgtgttctg acaagttgca aatattgagt ag at atc 161
 Asp Ile

gca tcc gtt agt gga gaa cta tgc gag aaa gct agc aag aca tgg tgg 209
 Ala Ser Val Ser Gly Glu Leu Cys Glu Lys Ala Ser Lys Thr Trp Ser
 25 30 35

gga aac tgt ggc aat acg gga cat tgt gac aac caa tgt aaa tca tgg 257
 Gly Asn Cys Gly Asn Thr Gly His Cys Asp Asn Gln Cys Lys Ser Trp
 40 45 50 55

gag ggt gcg gcc cat gga gcg tgt cat gtg cgt aac ggg aaa cac atg 305
 Glu Gly Ala Ala His Gly Ala Cys His Val Arg Asn Gly Lys His Met
 60 65 70

tgt ttc tgt tac ttc aat tgt aaa aaa gcc gaa aag ctt gct caa gac 353
 Cys Phe Cys Tyr Phe Asn Cys Lys Lys Ala Glu Lys Leu Ala Gln Asp
 75 80 85

aaa ctt aaa gcc gaa caa ctc gct caa gac aaa ctt aat gcc caa aag 401
 Lys Leu Lys Ala Glu Gln Leu Ala Gln Asp Lys Leu Asn Ala Gln Lys
 90 95 100

ctt gac cgt gat gcc aag aaa gtg gtt cca aac gtt gaa cat ccg 446
 Leu Asp Arg Asp Ala Lys Lys Val Val Pro Asn Val Glu His Pro
 105 110 115

<210> 6

<211> 150

<212> DNA

<213> Dahlia merckii

<400> 6

gagcttttgcg agaaggcttc taagacttgg tctggaaact gcggaaacac tggacattgc 60
 gataaccaat gcaagtcttg ggaggagct gctcatggag cttgccatgt tagaaacgga 120
 aagcatatgt gcttctgcta cttcaactgc. 150

<210> 7

<211> 60

<212> DNA

<213> Dahlia merckii

<400> 7

gaggtttgcg agaaggcttc taagacttgg tctggaaact gcggaaacac tggacattgc 60

<210> 8

<211> 111

<212> PRT

<213> Dahlia merckii

<400> 8

Met Ala Lys Asn Ser Val Ala Phe Phe Ala Leu Cys Leu Leu Leu Phe

1

5

10

15

Ile Leu Ala Ile Ser Glu Ile Arg Ser Val Lys Gly Glu Leu Cys Glu

20

25

30

Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Arg His Cys

35

40

45

Asp Asp Gln Cys Lys Ser Trp Glu Gly Ala Ala His Gly Ala Cys His

50

55

60

Val Arg Gly Gly Lys His Met Cys Phe Cys Tyr Phe Asn Cys Pro Lys

65

70

75

80

Ala Gln Lys Leu Ala Glu Asp Lys Leu Arg Ala Ala Glu Leu Ala Lys

85

90

95

Glu Lys Asn Asn Ile Gly Ala Glu Lys Val Pro Ser Ala Thr Pro

100

105

110

T06740"5T033250

9

<210> 9

<211> 108

<212> PRT

<213> Dahlia merckii

<400> 9

Met Ala Lys Asn Ser Val Ala Phe Leu Ala Phe Leu Leu Leu Leu Phe
1 5 10 15

Val Leu Ala Ile Ser Glu Ile Gly Ser Val Lys Gly Glu Leu Cys Glu
20 25 30

Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Arg His Cys
35 40 45

Asp Asp Gln Cys Lys Ser Trp Glu Gly Ala Ala His Gly Ala Cys His
50 55 60

Val Arg Gly Gly Lys His Met Cys Phe Cys Tyr Phe Asn Cys Ser Lys
65 70 75 80

Ala Gln Lys Leu Ala Gln Asp Lys Leu Lys Ala Asp Lys Leu Ala Lys
85 90 95

Glu Lys Ser Glu Ala Glu Lys Val Pro Ala Thr Pro
100 105

<210> 10

<211> 98

<212> PRT

<213> Dahlia merckii

<400> 10

Met Ala Lys Asn Ser Val Ala Phe Phe Ala Phe Val Leu Leu Leu Phe
1 5 10 15

10

Val Leu Ala Ile Ser Glu Ile Gly Ser Val Lys Gly Glu Leu Cys Glu
 20 25 30

Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Ile Thr Ser His Cys
 35 40 45

Asp Asn Gln Cys Arg Ser Trp Glu Gly Ala Ile His Gly Ala Cys His
 50 55 60

Val Arg Gly Gly Lys His Met Cys Phe Cys Tyr Phe Asn Cys Ser Lys
 65 70 75 80

Ala Asp Glu Leu Ala Lys Glu Lys Ile Glu Ala Glu Lys Met Pro Ala
 85 90 95

Thr Pro

<210> 11

<211> 108

<212> PRT

<213> Dahlia merckii

<400> 11

Met Val Asn Arg Ser Val Ala Phe Ser Val Phe Val Leu Ile Leu Phe
 1 5 10 15

Val Leu Ala Ile Ser Asp Ile Thr Ser Val Arg Gly Glu Val Cys Glu
 20 25 30

Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Gly His Cys
 35 40 45

Asp Asn Gln Cys Lys Tyr Trp Glu Gly Ala Ala His Gly Ala Cys His
 50 55 60

Val Arg Gly Gly Lys His Met Cys Phe Cys Tyr Phe Lys Cys Pro Lys
 65 70 75 80

09309-460

11

Ala Glu Lys Leu Ala Gln Asp Lys Val Asn Ala Gln Glu Leu Asp Arg
85 90 95

Asp Ala Lys Lys Val Ile Pro Asn Val Glu His Pro
100 105

<210> 12

<211> 118

<212> PRT

<213> Dahlia merckii

<400> 12

Met Val Asn Arg Ser Val Ala Phe Ser Ala Phe Val Leu Ile Leu Phe
1 5 10 15

Val Leu Ala Ile Ser Asp Ile Ala Ser Val Ser Gly Glu Leu Cys Glu
20 25 30

Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Gly His Cys
35 40 45

Asp Asn Gln Cys Lys Ser Trp Glu Gly Ala Ala His Gly Ala Cys His
50 55 60

Val Arg Asn Gly Lys His Met Cys Phe Cys Tyr Phe Asn Cys Lys Lys
65 70 75 80

Ala Glu Lys Leu Ala Gln Asp Lys Leu Lys Ala Glu Gln Leu Ala Gln
85 90 95

Asp Lys Leu Asn Ala Gln Lys Leu Asp Arg Asp Ala Lys Lys Val Val
100 105 110

Pro Asn Val Glu His Pro
115

T00429-5T030260

12

<210> 13

<211> 8

<212> PRT

<213> Dahlia merckii

<400> 13

Cys Glu Lys Ala Ser Lys Thr Trp

1

5

<210> 14

<211> 8

<212> PRT

<213> Dahlia merckii

<400> 14

Met Cys Phe Cys Tyr Phe Asn Cys

1

5

<210> 15

<211> 126

<212> DNA

<213> Dahlia merckii

<400> 15

aagacgtggt cgggaaactg tggcaatagc ggacattgtg acaaccaatg taaatcatgg 60
gaggggtgcgg cccatggagc gtgtcatgtg cgtaatggga aacacatgtg tttctgctac 120
ttcaac 126

<210> 16

<211> 42

<212> PRT

<213> Dahlia merckii

13

<400> 16

Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Gly His Cys Asp Asn Gln

1

5

10

15

Cys Lys Ser Trp Glu Gly Ala Ala His Gly Ala Cys His Val Arg Asn

20

25

30

Gly Lys His Met Cys Phe Cys Tyr Phe Asn

35

40

<210> 17

<211> 8

<212> PRT

<213> Dahlia merckii

<220>

<221> SITE

<222> (2)

<223> Xaa=Ala or Val

<220>

<221> SITE

<222> (3)

<223> Xaa=Lys or Asn

<220>

<221> SITE

<222> (4)

<223> Xaa=Asn or Arg

<400> 17

Met Xaa Xaa Xaa Ser Val Ala Phe

1

5

09763019 071901

14

<210> 18

<211> 7

<212> PRT

<213> Dahlia merckii

<400> 18

Asn Gly Lys His Met Cys Phe

1

5

<210> 19

<211> 7

<212> PRT

<213> Dahlia merckii

<400> 19

Gly Ala Cys His Val Arg Asn

1

5

<210> 20

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<221> misc_feature

<222> (6, 9, 12, 15, 21)

<223> n is any residue

<220>

<223> Description of Artificial Sequence:

Oligonucleotide

<400> 20

tgyganaang cnwsnaarac ntgg

24

<210> 21
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (9, 12, 15)
<223> n is any residue

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 21
cartttraant ancanaaaarc acat

24

<210> 22
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221> misc_feature
<222> (9, 12, 21)
<223> n is any residue

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 22
atggcsaanm rntcrgttgc ntt

23

PCT/GB99/02720

16

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

Oligonucleotide

<400> 23

aaacacatgt gtttcccatt

20

<210> 24

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

Oligonucleotide

<400> 24

agcgtgtcat gtgcgtaat

19

<210> 25

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

Oligonucleotide

<400> 25

taaagaaacc gaccctttca cgg

23

097300910404

17

<210> 26

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

Oligonucleotide

<400> 26

atcgtagcca tggatgaatcg gtcggttgcg ttctccgcg

39

<210> 27

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

Oligonucleotide

<400> 27

aaaccgaccg agctcacgga tgttcaacgt ttggaac

37

<210> 28

<211> 107

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

Oligonucleotide

<400> 28

atgcatccat ggtgaatcgg tcggttgcggt tctccgcggt cgttctgac cttttcgtgc 60

tcgccatctc agatatcgca tccgttagtg gagaactatg cgagaaa

107

<210> 29

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 29

agcaagcttt tcgggagctc aacaattgaa gtaa

34

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 30

aggaagttca tttcatttgg

20

<210> 31

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 31

gcctttggca caacttctgc ctctttccga tgagttgttc ggctttaagt ttgtc

55

19

<210> 32

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 32

ttagagctcc tattaacaag gaaagtagc

29

<210> 33

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 33

Ile Gly Lys Arg

1

<210> 34

<211> 534

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (76)..(525)

573303-074904
T06T20-5T03263

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 34

ctcgagtatt ttacaacaa ttaccaacaa caacaacaa caaacaacat tacaattact 60

atttacaatt acacc atg gtg aat cgg tcg gtt gcg ttc tcc gcg ttc gtt 111

Met Val Asn Arg Ser Val Ala Phe Ser Ala Phe Val

1

5

10

ctg atc ctt ttc gtg ctc gcc atc tca gat atc gca tcc gtt agt gga 159

Leu Ile Leu Phe Val Leu Ala Ile Ser Asp Ile Ala Ser Val Ser Gly

15

20

25

gaa cta tgc gag aaa gct agc aag acg tgg tcg ggc aac tgt ggc aac 207

Glu Leu Cys Glu Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn

30

35

40

acg gga cat tgt gac aac caa tgt aaa tca tgg gag ggt gcg gcc cat 255

Thr Gly His Cys Asp Asn Gln Cys Lys Ser Trp Glu Gly Ala Ala His

45

50

55

60

gga gcg tgt cat gtg cgt aac ggg aaa cac atg tgt ttc tgt tac ttc 303

Gly Ala Cys His Val Arg Asn Gly Lys His Met Cys Phe Cys Tyr Phe

65

70

75

aat tgt aaa aaa gcc gaa aag ctt gct caa gac aaa ctt aaa gcc gaa 351

Asn Cys Lys Lys Ala Glu Lys Leu Ala Gln Asp Lys Leu Lys Ala Glu

80

85

90

caa ctc atc gga aag agg cag aag ttg tgc caa agg cca agt ggg aca 399

Gln Leu Ile Gly Lys Arg Gln Lys Leu Cys Gln Arg Pro Ser Gly Thr

95

100

105

tgg tca gga gtc tgt gga aac aat aac gca tgc aag aat cag tgc att 447

Trp Ser Gly Val Cys Gly Asn Asn Asn Ala Cys Lys Asn Gln Cys Ile

110

115

120

21

aga ctt gag aaa gca cga cat gga tct tgc aac tat gtc ttc cca gct 495
 Arg Leu Glu Lys Ala Arg His Gly Ser Cys Asn Tyr Val Phe Pro Ala
 125 130 135 140

cac aag tgt atc tgc tac ttt cct tgt taa taggagctc 534
 His Lys Cys Ile Cys Tyr Phe Pro Cys
 145 150

<210> 35

<211> 149

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Synthetic
 sequence

<400> 35

Met Val Asn Arg Ser Val Ala Phe Ser Ala Phe Val Leu Ile Leu Phe
 1 5 10 15

Val Leu Ala Ile Ser Asp Ile Ala Ser Val Ser Gly Glu Leu Cys Glu
 20 25 30

Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Gly His Cys
 35 40 45

Asp Asn Gln Cys Lys Ser Trp Glu Gly Ala Ala His Gly Ala Cys His
 50 55 60

Val Arg Asn Gly Lys His Met Cys Phe Cys Tyr Phe Asn Cys Lys Lys
 65 70 75 80

Ala Glu Lys Leu Ala Gln Asp Lys Leu Lys Ala Glu Gln Leu Ile Gly
 85 90 95

Lys Arg Gln Lys Leu Cys Gln Arg Pro Ser Gly Thr Trp Ser Gly Val
 100 105 110

0976364 0799
 406470 6463760

22

Cys Gly Asn Asn Asn Ala Cys Lys Asn Gln Cys Ile Arg Leu Glu Lys
 115 120 125

Ala Arg His Gly Ser Cys Asn Tyr Val Phe Pro Ala His Lys Cys Ile
 130 135 140

Cys Tyr Phe Pro Cys
 145

<210> 36

<211> 316

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (76)..(312)

<220>

<223> Description of Artificial Sequence: Synthetic
 sequence

<400> 36

ctcgagtatt tttaacaaca ttaccaaca caacaaacaa caaacaacat tacaattact 60

atttacaatt acacc atg gtg aat cgg tcg gtt gcg ttc tcc gcg ttc gtt 111

Met Val Asn Arg Ser Val Ala Phe Ser Ala Phe Val

1

5

10

ctg atc ctt ttc gtg ctc gcc atc tca gat atc gca tcc gtt agt gga 159

Leu Ile Leu Phe Val Leu Ala Ile Ser Asp Ile Ala Ser Val Ser Gly

15

20

25

gaa cta tgc gag aaa gct agc aag acg tgg tcg ggc aac tgt ggc aac 207

Glu Leu Cys Glu Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn

30

35

40

23

acg gga cat tgt gac aac caa tgt aaa tca tgg gag ggt gcg gcc cat 255
 Thr Gly His Cys Asp Asn Gln Cys Lys Ser Trp Glu Gly Ala Ala His
 45 50 55 60

gga gcg tgt cat gtg cgt aat ggg aaa cac atg tgt ttc tgt tac ttc 303
 Gly Ala Cys His Val Arg Asn Gly Lys His Met Cys Phe Cys Tyr Phe
 65 70 75

aat tgt tga gctc 316
 Asn Cys

<210> 37

<211> 78

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Synthetic
 sequence

<400> 37

Met Val Asn Arg Ser Val Ala Phe Ser Ala Phe Val Leu Ile Leu Phe
 1 5 10 15

Val Leu Ala Ile Ser Asp Ile Ala Ser Val Ser Gly Glu Leu Cys Glu
 20 25 30

Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Gly His Cys
 35 40 45

Asp Asn Gln Cys Lys Ser Trp Glu Gly Ala Ala His Gly Ala Cys His
 50 55 60

Val Arg Asn Gly Lys His Met Cys Phe Cys Tyr Phe Asn Cys
 65 70 75

09763049-074901
 09763049-074901

SEQUENCE LISTING

<110> Evans, Ian
Ray, John

<120> Polynucleotide Sequences

<130> PPD50355/UST

<140>

<141>

<150> GB 9818003.7

<151> 1998-08-18

<150> PCT/GB99/02720

<151> 1999-08-17

<160> 37

<170> PatentIn Ver. 2.1

<210> 1

<211> 399

<212> DNA

<213> Dahlia merckii

<220>

<221> CDS

<222> (53)..(388)

<400> 1

gtgccccggg tcacgaagtt cggcacatct tagcggtatg cataagtcaa aa atg gcc 58
Met Ala
1

aaa aat tca gtt gct ttc ttt gca ttg tgc ctg ctt ctt ttc att ctt 106
Lys Asn Ser Val Ala Phe Phe Ala Leu Cys Leu Leu Leu Phe Ile Leu
5 10 15

gct atc tca gaa atc aga tcg gtg aag ggg gaa tta tgt gag aag gca 154
Ala Ile Ser Glu Ile Arg Ser Val Lys Gly Glu Leu Cys Glu Lys Ala
20 25 30

agc aag aca tgg tct gga aat tgt ggc aat aca aga cac tgt gat gac 202
Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Arg His Cys Asp Asp
35 40 45 50

cag tgc aag tct tgg gag ggt gca gcc cat gga gct tgt cac gtg cgc 250
Gln Cys Lys Ser Trp Glu Gly Ala Ala His Gly Ala Cys His Val Arg
55 60 65

ggg ggg aaa cac atg tgc ttc tgc tac ttc aac tgt ccc aaa gcc cag 298
Gly Gly Lys His Met Cys Phe Cys Tyr Phe Asn Cys Pro Lys Ala Gln
70 75 80

aag ttg gct gag gat aaa ctc aga gca gca gag cta gca aag gag aag 346
Lys Leu Ala Glu Asp Lys Leu Arg Ala Ala Glu Leu Ala Lys Glu Lys
85 90 95

09/763019-01901

aat aat att gga gct gaa aag gtg cct tca gcc aca cct tga 388
 Asn Asn Ile Gly Ala Glu Lys Val Pro Ser Ala Thr Pro
 100 105 110

gtactaacaa a 399

<210> 2
 <211> 523
 <212> DNA
 <213> Dahlia merckii

<220>
 <221> CDS
 <222> (11)..(337)

<400> 2
 ggcacgagta atg gcc aaa aat tca gtt gct ttc tta gca ttt ctt ctg 49
 Met Ala Lys Asn Ser Val Ala Phe Leu Ala Phe Leu Leu
 1 5 10

ctt ctt ttc gtt ctt gct atc tca gaa atc gga tgc gtg aag ggg gaa 97
 Leu Leu Phe Val Leu Ala Ile Ser Glu Ile Gly Ser Val Lys Gly Glu
 15 20 25

tta tgt gag aag gca agc aag aca tgg tct gga aat tgt ggc aat aca 145
 Leu Cys Glu Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr
 30 35 40 45

aga cac tgt gat gac cag tgc aag tct tgg gag ggc gca gcc cat gga 193
 Arg His Cys Asp Asp Gln Cys Lys Ser Trp Glu Gly Ala Ala His Gly
 50 55 60

gct tgt cac gtg cgc ggt ggg aaa cac atg tgc ttt tgc tac ttc aac 241
 Ala Cys His Val Arg Gly Gly Lys His Met Cys Phe Cys Tyr Phe Asn
 65 70 75

tgt tcc aaa gcc cag aag ctg gct cag gat aaa ctc aaa gcc gac aag 289
 Cys Ser Lys Ala Gln Lys Leu Ala Gln Asp Lys Leu Lys Ala Asp Lys
 80 85 90

ctc gcc aag gag aag agt gaa gcc gaa aag gtg cca gct aca cct tga 337
 Leu Ala Lys Glu Lys Ser Glu Ala Glu Lys Val Pro Ala Thr Pro
 95 100 105

gtactaacaa gtgttgtagt attatgaata aagagaaaat gctttctagt taccatattt 397

agcattctct aatgtgtaat gtttggtgct tttggaacta attgtttaac tatgattcca 457

gctaataatg ttttaagtat ataataaag ttatcttatt ttgaagcctg taaaaaaaaa 517

aaaaaa 523

<210> 3
 <211> 385
 <212> DNA

097670067069650

<213> Dahlia merckii

<220>

<221> CDS

<222> (24)..(320)

<400> 3

```

cggcacgagg cacaatctca aaa atg gcc aaa aat tcg gtt gct ttc ttt gca 53
                Met Ala Lys Asn Ser Val Ala Phe Phe Ala
                  1             5             10

ttt gtc ctg ctt ctt ttc gtt ctt gct atc tca gaa att gga tcg gtg 101
Phe Val Leu Leu Leu Phe Val Leu Ala Ile Ser Glu Ile Gly Ser Val
                15             20             25

aag gga gaa tta tgt gag aag gca agc aag aca tgg tct gga aat tgt 149
Lys Gly Glu Leu Cys Glu Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys
                30             35             40

ggc atc aca tca cac tgt gac aac cag tgc cgg tcg tgg gag ggt gca 197
Gly Ile Thr Ser His Cys Asp Asn Gln Cys Arg Ser Trp Glu Gly Ala
                45             50             55

atc cat gga gct tgt cac gtg cgc ggt ggg aaa cac atg tgc ttc tgc 245
Ile His Gly Ala Cys His Val Arg Gly Gly Lys His Met Cys Phe Cys
                60             65             70

tac ttc aac tgt tcc aaa gcc gat gag ctc gcg aag gag aag att gaa 293
Tyr Phe Asn Cys Ser Lys Ala Asp Glu Leu Ala Lys Glu Lys Ile Glu
                75             80             85             90

gcc gaa aag atg cca gcc aca cct tga gtactaacaa atgctatatg 340
Ala Glu Lys Met Pro Ala Thr Pro
                95

attataaata aagagaaaat gcttttctaaa aaaaaaaaaa aaaaaa 385

```

<210> 4

<211> 577

<212> DNA

<213> Dahlia merckii

<220>

<221> CDS

<222> (20)..(346)

<400> 4

```

ggcacgagcc tattaataaa atg gtg aat cga tcg gtt gct ttc tcc gtg ttc 52
                Met Val Asn Arg Ser Val Ala Phe Ser Val Phe
                  1             5             10

gtt ctg atc ctt ttc gtg ctc gcc atc tca gat atc aca agt gtg aga 100
Val Leu Ile Leu Phe Val Leu Ala Ile Ser Asp Ile Thr Ser Val Arg
                15             20             25

gga gaa gta tgc gag aaa gct agc aag aca tgg tca gga aac tgt ggc 148
Gly Glu Val Cys Glu Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly
                30             35             40

```

09763049.07.1904

aac acg gga cac tgt gac aac caa tgt aaa tac tgg gag ggg gcg gcc 196
 Asn Thr Gly His Cys Asp Asn Gln Cys Lys Tyr Trp Glu Gly Ala Ala
 45 50 55

cat ggg gcg tgc cac gtg cgt gga ggg aaa cac atg tgt ttc tgc tac 244
 His Gly Ala Cys His Val Arg Gly Gly Lys His Met Cys Phe Cys Tyr
 60 65 70 75

ttc aag tgt ccc aaa gcc gaa aag ctt gct caa gac aaa gtt aat gcc 292
 Phe Lys Cys Pro Lys Ala Glu Lys Leu Ala Gln Asp Lys Val Asn Ala
 80 85 90

caa gag ctt gac cgt gat gcc aag aaa gtg att ccg aac gtt gaa cat 340
 Gln Glu Leu Asp Arg Asp Ala Lys Lys Val Ile Pro Asn Val Glu His
 95 100 105

ccg tga aagggtcggg ttcttttaaat agaaagtctt agattacgaa tgcgaataac 396
 Pro

tatagaaaat gtttgctaaa tgtcacatta taattagaac tttatgattg ttgtcaatag 456

ggcattttct tgtagtgat atgtgtaata aggtgatgct tttatgcttt tcgtgcgtaa 516

gagttttcga ctatgtgtaa taaagaaagg gtcttttttt tttaaaaaaa aaaaaaaaaa 576

a 577

<210> 5

<211> 446

<212> DNA

<213> Dahlia merckii

<400> 5

atggtgaatc ggtcgggtgc gttctccgcg ttcgttctga tctttttcgt gctcgccatc 60
 tcagggttatc aaatcttttag ttcattttatt gaatatgata gtattttatat tctttttatgg 120
 ttttatgtgt tctgacaagt tgcaaatatt gagtagatat cgcattccgtt agtggagaac 180
 tatgogagaa agctagcaag acatggtcgg gaaactgtgg caatacggga cattgtgaca 240
 accaatgtaa atcatgggag ggtgcggccc atggagcgtg tcatgtgcgt aacgggaaac 300
 acatgtgttt ctgttacttc aattgtaaaa aagccgaaaa gcttgctcaa gacaaactta 360
 aagccgaaca actcgtctca gacaaactta atgcccaaaa gcttgaccgt gatgccaaga 420
 aagtggttcc aaacgttgaa catccg 446

<210> 6

<211> 150

<212> DNA

<213> Dahlia merckii

<400> 6

gagctttgcg agaaggcttc taagacttgg tctggaaact gcggaacac tggacattgc 60
 gataaccaat gcaagtcttg ggagggagct gctcatggag cttgccatgt tagaaacgga 120
 aagcatatgt gcttctgcta cttcaactgc 150

<210> 7

<211> 60

<212> DNA

<213> Dahlia merckii

0576305.01901

<400> 7
gaggtttgcg agaaggcttc taagacttgg tctggaaact gcggaaacac tggacattgc 60

<210> 8
<211> 111
<212> PRT
<213> Dahlia merckii

<400> 8
Met Ala Lys Asn Ser Val Ala Phe Phe Ala Leu Cys Leu Leu Leu Phe
1 5 10 15
Ile Leu Ala Ile Ser Glu Ile Arg Ser Val Lys Gly Glu Leu Cys Glu
20 25 30
Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Arg His Cys
35 40 45
Asp Asp Gln Cys Lys Ser Trp Glu Gly Ala Ala His Gly Ala Cys His
50 55 60
Val Arg Gly Gly Lys His Met Cys Phe Cys Tyr Phe Asn Cys Pro Lys
65 70 75 80
Ala Gln Lys Leu Ala Glu Asp Lys Leu Arg Ala Ala Glu Leu Ala Lys
85 90 95
Glu Lys Asn Asn Ile Gly Ala Glu Lys Val Pro Ser Ala Thr Pro
100 105 110

<210> 9
<211> 108
<212> PRT
<213> Dahlia merckii

<400> 9
Met Ala Lys Asn Ser Val Ala Phe Leu Ala Phe Leu Leu Leu Leu Phe
1 5 10 15
Val Leu Ala Ile Ser Glu Ile Gly Ser Val Lys Gly Glu Leu Cys Glu
20 25 30
Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Arg His Cys
35 40 45
Asp Asp Gln Cys Lys Ser Trp Glu Gly Ala Ala His Gly Ala Cys His
50 55 60
Val Arg Gly Gly Lys His Met Cys Phe Cys Tyr Phe Asn Cys Ser Lys
65 70 75 80
Ala Gln Lys Leu Ala Gln Asp Lys Leu Lys Ala Asp Lys Leu Ala Lys
85 90 95
Glu Lys Ser Glu Ala Glu Lys Val Pro Ala Thr Pro
100 105

<210> 10

0976303907001

<211> 98
 <212> PRT
 <213> Dahlia merckii

<400> 10

Met Ala Lys Asn Ser Val Ala Phe Phe Ala Phe Val Leu Leu Leu Phe
 1 5 10 15
 Val Leu Ala Ile Ser Glu Ile Gly Ser Val Lys Gly Glu Leu Cys Glu
 20 25 30
 Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Ile Thr Ser His Cys
 35 40 45
 Asp Asn Gln Cys Arg Ser Trp Glu Gly Ala Ile His Gly Ala Cys His
 50 55 60
 Val Arg Gly Gly Lys His Met Cys Phe Cys Tyr Phe Asn Cys Ser Lys
 65 70 75 80
 Ala Asp Glu Leu Ala Lys Glu Lys Ile Glu Ala Glu Lys Met Pro Ala
 85 90 95
 Thr Pro

<210> 11
 <211> 108
 <212> PRT
 <213> Dahlia merckii

<400> 11

Met Val Asn Arg Ser Val Ala Phe Ser Val Phe Val Leu Ile Leu Phe
 1 5 10 15
 Val Leu Ala Ile Ser Asp Ile Thr Ser Val Arg Gly Glu Val Cys Glu
 20 25 30
 Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Gly His Cys
 35 40 45
 Asp Asn Gln Cys Lys Tyr Trp Glu Gly Ala Ala His Gly Ala Cys His
 50 55 60
 Val Arg Gly Gly Lys His Met Cys Phe Cys Tyr Phe Lys Cys Pro Lys
 65 70 75 80
 Ala Glu Lys Leu Ala Gln Asp Lys Val Asn Ala Gln Glu Leu Asp Arg
 85 90 95
 Asp Ala Lys Lys Val Ile Pro Asn Val Glu His Pro
 100 105

<210> 12
 <211> 118
 <212> PRT
 <213> Dahlia merckii

<400> 12

Met Val Asn Arg Ser Val Ala Phe Ser Ala Phe Val Leu Ile Leu Phe
 1 5 10 15

096303 01501

```

<210> 13
<211> 8
<212> PRT
<213> Dahlia merckii

<400> 13
Cys Glu Lys Ala Ser Lys Thr Trp
  1                               5

<210> 14
<211> 8
<212> PRT
<213> Dahlia merckii

<400> 14
Met Cys Phe Cys Tyr Phe Asn Cys
  1                               5

```

```
<210> 16
<211> 42
<212> PRT
<213> Dahlia merckii
```

<400> 16
 Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Gly His Cys Asp Asn Gln
 1 5 10 15
 Cys Lys Ser Trp Glu Gly Ala Ala His Gly Ala Cys His Val Arg Asn
 20 25 30
 Gly Lys His Met Cys Phe Cys Tyr Phe Asn
 35 40

<210> 17
 <211> 8
 <212> PRT
 <213> Dahlia merckii

<220>
 <221> SITE
 <222> (2)
 <223> Xaa is Ala or Val

<220>
 <221> SITE
 <222> (3)
 <223> Xaa is Lys or Asn

<220>
 <221> SITE
 <222> (4)
 <223> Xaa is Asn or Arg

<400> 17
 Met Xaa Xaa Xaa Ser Val Ala Phe
 1 5

<210> 18
 <211> 7
 <212> PRT
 <213> Dahlia merckii

<400> 18
 Asn Gly Lys His Met Cys Phe
 1 5

<210> 19
 <211> 7
 <212> PRT
 <213> Dahlia merckii

<400> 19
 Gly Ala Cys His Val Arg Asn
 1 5

096043 071901
 106140 " 6T0F9V60

<210> 20
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:
 Oligonucleotide

<220>
 <221> misc_feature
 <222> (6)
 <223> n is any residue

<220>
 <221> misc_feature
 <222> (9)
 <223> n is any residue

<220>
 <221> misc_feature
 <222> (12)
 <223> n is any residue

<220>
 <221> misc_feature
 <222> (15)
 <223> n is any residue

<220>
 <221> misc_feature
 <222> (21)
 <223> n is any residue

<400> 20
 tgyganaang cnwsnaarac ntgg

24

<210> 21
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:
 Oligonucleotide

<220>
 <221> misc_feature
 <222> (9)
 <223> n is any residue

<220>
 <221> misc_feature
 <222> (12)
 <223> n is any residue

<220>
 <221> misc_feature
 <222> (15)
 <223> n is any residue

0960940604

<400> 21
carttraant ancaaaaarc acat 24

<210> 22
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<220>
<221> misc_feature
<222> (9)
<223> n is any residue

<220>
<221> misc_feature
<222> (12)
<223> n is any residue

<220>
<221> misc_feature
<222> (21)
<223> n is any residue

<400> 22
atggcsaanm rntcrgttgc ntt 23

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 23
aaacacatgt gtttccatt 20

<210> 24
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 24
agcgtgtcat gtgcgtaat 19

<210> 25
<211> 23

0963049 074901
T05T20 5T059260

<400> 29

agcaagcttt tcgggagctc aacaattgaa gtaa

34

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 30

aggaagttca tttcatttgg

20

<210> 31

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 31

gcctttggca caacttctgc ctctttccga tgagttgttc ggctttaagt ttgtc

55

<210> 32

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 32

ttagagctcc tattaacaag gaaagtagc

29

<210> 33

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 33

Ile Gly Lys Arg

1

<210> 34

<211> 534

<212> DNA

<213> Artificial Sequence

096067060

<220>

<221> CDS

<222> (76)..(525)

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 34

ctcgagtatt ttacacaaca ttaccaacaa caacaaacaa caaacaacat tacaattact 60

atttacaatt	acacc	atg	gtg	aat	cgg	tcg	gtt	gcg	ttc	tcc	gcg	ttc	gtt	111
	Met	Val	Asn	Arg	Ser	Val	Ala	Phe	Ser	Ala	Phe	Val		
	1				5					10				

ctg	atc	ctt	ttc	gtg	ctc	gcc	atc	tca	gat	atc	gca	tcc	gtt	agt	gga	159
Leu	Ile	Leu	Phe	Val	Leu	Ala	Ile	Ser	Asp	Ile	Ala	Ser	Val	Ser	Gly	
	15				20						25					

gaa	cta	tgc	gag	aaa	gct	agc	aag	acg	tgg	tcg	ggc	aac	tgt	ggc	aac	207
Glu	Leu	Cys	Glu	Lys	Ala	Ser	Lys	Thr	Trp	Ser	Gly	Asn	Cys	Gly	Asn	
	30				35					40						

acg	gga	cat	tgt	gac	aac	caa	tgt	aaa	tca	tgg	gag	ggg	gcg	gcc	cat	255
Thr	Gly	His	Cys	Asp	Asn	Gln	Cys	Lys	Ser	Trp	Glu	Gly	Ala	Ala	His	
	45				50				55					60		

gga	gcg	tgt	cat	gtg	cgt	aac	ggg	aaa	cac	atg	tgt	ttc	tgt	tac	ttc	303
Gly	Ala	Cys	His	Val	Arg	Asn	Gly	Lys	His	Met	Cys	Phe	Cys	Tyr	Phe	
				65				70						75		

aat	tgt	aaa	aaa	gcc	gaa	aag	ctt	gct	caa	gac	aaa	ctt	aaa	gcc	gaa	351
Asn	Cys	Lys	Lys	Ala	Glu	Lys	Leu	Ala	Gln	Asp	Lys	Leu	Lys	Ala	Glu	
		80					85					90				

caa	ctc	atc	gga	aag	agg	cag	aag	ttg	tgc	caa	agg	cca	agt	ggg	aca	399
Gln	Leu	Ile	Gly	Lys	Arg	Gln	Lys	Leu	Cys	Gln	Arg	Pro	Ser	Gly	Thr	
	95					100						105				

tgg	tca	gga	gtc	tgt	gga	aac	aat	aac	gca	tgc	aag	aat	cag	tgc	att	447
Trp	Ser	Gly	Val	Cys	Gly	Asn	Asn	Ala	Cys	Lys	Asn	Gln	Cys	Ile		
	110				115					120						

aga	ctt	gag	aaa	gca	cga	cat	gga	tct	tgc	aac	tat	gtc	ttc	cca	gct	495
Arg	Leu	Glu	Lys	Ala	Arg	His	Gly	Ser	Cys	Asn	Tyr	Val	Phe	Pro	Ala	
	125			130					135					140		

cac	aag	tgt	atc	tgc	tac	ttt	cct	tgt	taa	taggagctc	534
His	Lys	Cys	Ile	Cys	Tyr	Phe	Pro	Cys			
		145									

<210> 35

<211> 149

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

T05T20"ST0E9Z60

<400> 35

Met Val Asn Arg Ser Val Ala Phe Ser Ala Phe Val Leu Ile Leu Phe
 1 5 10 15

Val Leu Ala Ile Ser Asp Ile Ala Ser Val Ser Gly Glu Leu Cys Glu
 20 25 30

Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Gly His Cys
 35 40 45

Asp Asn Gln Cys Lys Ser Trp Glu Gly Ala Ala His Gly Ala Cys His
 50 55 60

Val Arg Asn Gly Lys His Met Cys Phe Cys Tyr Phe Asn Cys Lys Lys
 65 70 75 80

Ala Glu Lys Leu Ala Gln Asp Lys Leu Lys Ala Glu Gln Leu Ile Gly
 85 90 95

Lys Arg Gln Lys Leu Cys Gln Arg Pro Ser Gly Thr Trp Ser Gly Val
 100 105 110

Cys Gly Asn Asn Asn Ala Cys Lys Asn Gln Cys Ile Arg Leu Glu Lys
 115 120 125

Ala Arg His Gly Ser Cys Asn Tyr Val Phe Pro Ala His Lys Cys Ile
 130 135 140

Cys Tyr Phe Pro Cys
 145

<210> 36

<211> 316

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (76)..(312)

<220>

<223> Description of Artificial Sequence: Synthetic
 sequence

<400> 36

ctcgagtatt tttaacaaca ttaccaacaa caacaacaa caaacaacat tacaattact 60

atttacaatt acacc atg gtg aat cgg tcg gtt gcg ttc tcc gcg ttc gtt 111
 Met Val Asn Arg Ser Val Ala Phe Ser Ala Phe Val
 1 5 10

ctg atc ctt ttc gtg ctc gcc atc tca gat atc gca tcc gtt agt gga 159
 Leu Ile Leu Phe Val Leu Ala Ile Ser Asp Ile Ala Ser Val Ser Gly
 15 20 25

gaa cta tgc gag aaa gct agc aag acg tgg tcg ggc aac tgt ggc aac 207
 Glu Leu Cys Glu Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn
 30 35 40

1259290670

acg gga cat tgt gac aac caa tgt aaa tca tgg gag ggt gcg gcc cat 255
 Thr Gly His Cys Asp Asn Gln Cys Lys Ser Trp Glu Gly Ala Ala His
 45 50 55 60

gga gcg tgt cat gtg cgt aat ggg aaa cac atg tgt ttc tgt tac ttc 303
 Gly Ala Cys His Val Arg Asn Gly Lys His Met Cys Phe Cys Tyr Phe
 65 70 75

aat tgt tga gctc 316
 Asn Cys

<210> 37
 <211> 78
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 sequence

<400> 37
 Met Val Asn Arg Ser Val Ala Phe Ser Ala Phe Val Leu Ile Leu Phe
 1 5 10 15

Val Leu Ala Ile Ser Asp Ile Ala Ser Val Ser Gly Glu Leu Cys Glu
 20 25 30

Lys Ala Ser Lys Thr Trp Ser Gly Asn Cys Gly Asn Thr Gly His Cys
 35 40 45

Asp Asn Gln Cys Lys Ser Trp Glu Gly Ala Ala His Gly Ala Cys His
 50 55 60

Val Arg Asn Gly Lys His Met Cys Phe Cys Tyr Phe Asn Cys
 65 70 75

05763049.07.1991